| 1 |
ClinicalTrials.gov (NCT03997123) Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290). U.S. National Institutes of Health.
|
| 2 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 3 |
ClinicalTrials.gov (NCT03562637) Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC. U.S. National Institutes of Health.
|
| 4 |
ClinicalTrials.gov (NCT01262027) TKI258 for Metastatic Inflammatory Breast Cancer Patients. U.S. National Institutes of Health.
|
| 5 |
ClinicalTrials.gov (NCT03184558) Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC. U.S. National Institutes of Health.
|
| 6 |
ClinicalTrials.gov (NCT04634747) A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients. U.S. National Institutes of Health.
|
| 7 |
ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|
| 8 |
ClinicalTrials.gov (NCT03674827) Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC. U.S. National Institutes of Health.
|
| 9 |
ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
|
| 10 |
ClinicalTrials.gov (NCT04115306) Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health.
|
| 11 |
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.
|
| 12 |
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011 Nov 11;286(45):39247-58.
|
| 13 |
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 1;105:23-33.
|
| 14 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570.
|
| 15 |
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.
|
| 16 |
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.J Exp Clin Cancer Res. 2019 Jul 15;38(1):309. doi: 10.1186/s13046-019-1294-9.
|
| 17 |
miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.Cancer Lett. 2019 Jul 10;454:224-233. doi: 10.1016/j.canlet.2019.04.006. Epub 2019 Apr 17.
|
| 18 |
Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.
|
| 19 |
Tetrandrine-Induced Autophagy in MDA-MB-231 Triple-Negative Breast Cancer Cell through the Inhibition of PI3K/AKT/mTOR Signaling.Evid Based Complement Alternat Med. 2019 Jan 1;2019:7517431. doi: 10.1155/2019/7517431. eCollection 2019.
|
| 20 |
MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.BMC Cancer. 2019 Jun 13;19(1):577. doi: 10.1186/s12885-019-5796-9.
|
| 21 |
3,17-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity.J Med Chem. 2019 Feb 28;62(4):2202-2212. doi: 10.1021/acs.jmedchem.8b01990. Epub 2019 Feb 18.
|
| 22 |
High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis.Oncol Lett. 2019 Sep;18(3):3249-3255. doi: 10.3892/ol.2019.10618. Epub 2019 Jul 15.
|
| 23 |
Cadherin 11 Inhibition Downregulates -catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer.J Clin Med. 2019 Jan 27;8(2):148. doi: 10.3390/jcm8020148.
|
| 24 |
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.Cancer Med. 2018 Apr;7(4):1349-1358. doi: 10.1002/cam4.1376. Epub 2018 Mar 9.
|
| 25 |
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.J Med Chem. 2019 May 9;62(9):4401-4410. doi: 10.1021/acs.jmedchem.8b01869. Epub 2019 Apr 30.
|
| 26 |
Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1.Oncogene. 2019 Jul;38(28):5725-5738. doi: 10.1038/s41388-019-0824-4. Epub 2019 Apr 23.
|
| 27 |
Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.Cell Prolif. 2018 Apr;51(2):e12402. doi: 10.1111/cpr.12402. Epub 2017 Nov 1.
|
| 28 |
Clonality of circulating tumor cells in breast cancer brain metastasis patients.Breast Cancer Res. 2019 Sep 3;21(1):101. doi: 10.1186/s13058-019-1184-2.
|
| 29 |
TGF1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer.Mol Oncol. 2018 Sep;12(9):1447-1463. doi: 10.1002/1878-0261.12355. Epub 2018 Jul 30.
|
| 30 |
Prognostic role of GPER/Ezrin in triple-negative breast cancer is associated with menopausal status.Endocr Connect. 2019 Jun 1;8(6):661-671. doi: 10.1530/EC-19-0164.
|
| 31 |
The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis.Biochem J. 2016 Feb 15;473(4):449-61. doi: 10.1042/BJ20150926. Epub 2015 Nov 27.
|
| 32 |
Folate Receptor -Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16.
|
| 33 |
The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.Cancer Lett. 2020 Jan 28;469:256-265. doi: 10.1016/j.canlet.2019.10.039. Epub 2019 Oct 28.
|
| 34 |
Exploring specific prognostic biomarkers in triple-negative breast cancer.Cell Death Dis. 2019 Oct 24;10(11):807. doi: 10.1038/s41419-019-2043-x.
|
| 35 |
Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.J Hematol Oncol. 2019 Jun 11;12(1):60. doi: 10.1186/s13045-019-0744-3.
|
| 36 |
Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.Breast Cancer Res Treat. 2018 Jun;169(3):427-436. doi: 10.1007/s10549-017-4641-6. Epub 2018 Feb 6.
|
| 37 |
Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer.Sci Rep. 2018 Oct 30;8(1):16008. doi: 10.1038/s41598-018-34502-8.
|
| 38 |
Cytotoxic Activity of the Histone Deacetylase 3-Selective Inhibitor Pojamide on MDA-MB-231 Triple-Negative Breast Cancer Cells.Int J Mol Sci. 2019 Feb 13;20(4):804. doi: 10.3390/ijms20040804.
|
| 39 |
Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [(68)Ga]DOTA-VAP.Mol Imaging Biol. 2020 Jun;22(3):772-779. doi: 10.1007/s11307-019-01416-4.
|
| 40 |
Up-regulation of cathepsin S expression by HSP90 and 5-HT(7) receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.Breast Cancer Res Treat. 2017 Jan;161(1):29-40. doi: 10.1007/s10549-016-4027-1. Epub 2016 Oct 27.
|
| 41 |
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.Eur J Med Chem. 2019 Aug 1;175:247-268. doi: 10.1016/j.ejmech.2019.04.047. Epub 2019 Apr 20.
|
| 42 |
The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.Breast Cancer Res. 2019 Apr 29;21(1):54. doi: 10.1186/s13058-019-1136-x.
|
| 43 |
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.Front Immunol. 2018 Sep 20;9:2140. doi: 10.3389/fimmu.2018.02140. eCollection 2018.
|
| 44 |
Stromal integrin 11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.BMC Cancer. 2019 Mar 15;19(1):234. doi: 10.1186/s12885-019-5449-z.
|
| 45 |
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Stem Cell Reports. 2017 May 9;8(5):1392-1407. doi: 10.1016/j.stemcr.2017.03.026. Epub 2017 Apr 27.
|
| 46 |
FOXM1 transcriptionally regulates expression of integrin 1 in triple-negative breast cancer.Breast Cancer Res Treat. 2017 Jun;163(3):485-493. doi: 10.1007/s10549-017-4207-7. Epub 2017 Mar 30.
|
| 47 |
Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development.Front Endocrinol (Lausanne). 2018 Apr 30;9:192. doi: 10.3389/fendo.2018.00192. eCollection 2018.
|
| 48 |
Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.Cancer Biomark. 2019;25(1):19-27. doi: 10.3233/CBM-182094.
|
| 49 |
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24.
|
| 50 |
An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.Sci Rep. 2019 Sep 16;9(1):13308. doi: 10.1038/s41598-019-49809-3.
|
| 51 |
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.Breast Cancer Res. 2019 Jan 14;21(1):5. doi: 10.1186/s13058-018-1094-8.
|
| 52 |
A novel metadherin7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFB-SIRT3 axis.Oncogene. 2020 Mar;39(10):2088-2102. doi: 10.1038/s41388-019-1126-6. Epub 2019 Dec 5.
|
| 53 |
NLRX1 regulates TNF--induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1460-1476. doi: 10.1016/j.bbadis.2019.02.018. Epub 2019 Feb 23.
|
| 54 |
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.Mol Oncol. 2017 Mar;11(3):266-279. doi: 10.1002/1878-0261.12033. Epub 2017 Feb 7.
|
| 55 |
High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.Breast Cancer Res. 2019 Nov 28;21(1):127. doi: 10.1186/s13058-019-1197-x.
|
| 56 |
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.Aging (Albany NY). 2019 Dec 4;11(23):11054-11072. doi: 10.18632/aging.102510. Epub 2019 Dec 4.
|
| 57 |
A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.Int J Mol Sci. 2019 Feb 28;20(5):1057. doi: 10.3390/ijms20051057.
|
| 58 |
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.Oncogene. 2019 Feb;38(7):1106-1120. doi: 10.1038/s41388-018-0499-2. Epub 2018 Sep 12.
|
| 59 |
Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-kB Activity in Triple-Negative Breast Cancer Cells.Mol Cells. 2019 Sep 30;42(9):628-636. doi: 10.14348/molcells.2019.0038.
|
| 60 |
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer.Lab Invest. 2019 Sep;99(9):1275-1286. doi: 10.1038/s41374-019-0247-4. Epub 2019 Apr 17.
|
| 61 |
Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model.Int J Med Sci. 2019 Nov 9;16(12):1642-1651. doi: 10.7150/ijms.38521. eCollection 2019.
|
| 62 |
PPAR Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.Mol Cancer Ther. 2017 Nov;16(11):2528-2542. doi: 10.1158/1535-7163.MCT-16-0739. Epub 2017 Aug 15.
|
| 63 |
Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3 activity.PLoS One. 2019 May 31;14(5):e0217789. doi: 10.1371/journal.pone.0217789. eCollection 2019.
|
| 64 |
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Mol Cancer Ther. 2016 Nov;15(11):2598-2608. doi: 10.1158/1535-7163.MCT-16-0106. Epub 2016 Aug 15.
|
| 65 |
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.Cells. 2019 Aug 30;8(9):1010. doi: 10.3390/cells8091010.
|
| 66 |
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.Oncogene. 2018 Oct;37(43):5701-5718. doi: 10.1038/s41388-018-0368-z. Epub 2018 Jun 18.
|
| 67 |
miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer.J Cell Biochem. 2019 Aug;120(8):12943-12948. doi: 10.1002/jcb.28565. Epub 2019 Mar 14.
|
| 68 |
Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.Cancer Res. 2019 Aug 15;79(16):4211-4226. doi: 10.1158/0008-5472.CAN-18-3803. Epub 2019 Jun 25.
|
| 69 |
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?.Expert Opin Investig Drugs. 2019 Feb;28(2):107-112. doi: 10.1080/13543784.2019.1555239. Epub 2018 Dec 17.
|
| 70 |
A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.Clin Cancer Res. 2013 Apr 15;19(8):2061-70. doi: 10.1158/1078-0432.CCR-13-0082. Epub 2013 Mar 11.
|
| 71 |
CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death.Cancer Cell Int. 2019 Feb 4;19:26. doi: 10.1186/s12935-019-0740-2. eCollection 2019.
|
| 72 |
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.Mol Cancer Ther. 2017 Dec;16(12):2892-2901. doi: 10.1158/1535-7163.MCT-17-0170. Epub 2017 Sep 27.
|
| 73 |
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.Clin Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0.
|
| 74 |
TRPC3 Regulates the Proliferation and Apoptosis Resistance of Triple Negative Breast Cancer Cells through the TRPC3/RASA4/MAPK Pathway.Cancers (Basel). 2019 Apr 18;11(4):558. doi: 10.3390/cancers11040558.
|
| 75 |
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.Neoplasia. 2018 May;20(5):478-488. doi: 10.1016/j.neo.2018.03.003. Epub 2018 Mar 30.
|
| 76 |
Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.Cancer Sci. 2019 Feb;110(2):561-567. doi: 10.1111/cas.13888. Epub 2019 Jan 4.
|
| 77 |
Expression of LXR? ABCA1 and ABCG1 in human triplenegative breast cancer tissues.Oncol Rep. 2019 Nov;42(5):1869-1877. doi: 10.3892/or.2019.7279. Epub 2019 Aug 14.
|
| 78 |
MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer.Cell Cycle. 2019 Oct;18(20):2641-2650. doi: 10.1080/15384101.2019.1653107. Epub 2019 Aug 14.
|
| 79 |
cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.Cell Death Differ. 2018 Dec;25(12):2147-2164. doi: 10.1038/s41418-018-0100-0. Epub 2018 Apr 19.
|
| 80 |
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.Cancer Med. 2019 Aug;8(9):4389-4403. doi: 10.1002/cam4.2335. Epub 2019 Jun 18.
|
| 81 |
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.Mol Cancer Res. 2019 Jul;17(7):1503-1518. doi: 10.1158/1541-7786.MCR-18-1121. Epub 2019 Apr 18.
|
| 82 |
Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.Oncotarget. 2018 Apr 10;9(27):18682-18697. doi: 10.18632/oncotarget.24588. eCollection 2018 Apr 10.
|
| 83 |
Cisplatin Induces Apoptosis Through the Endoplasmic Reticulum-mediated, Calpain 1 Pathway in Triple-negative Breast Cancer Cells.Clin Breast Cancer. 2017 Jun;17(3):e103-e112. doi: 10.1016/j.clbc.2016.12.001. Epub 2016 Dec 24.
|
| 84 |
Antrodia salmonea induces G(2) cell-cycle arrest in human triple-negative breast cancer (MDA-MB-231) cells and suppresses tumor growth in athymic nude mice.J Ethnopharmacol. 2017 Jan 20;196:9-19. doi: 10.1016/j.jep.2016.12.018. Epub 2016 Dec 14.
|
| 85 |
The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression.Mol Cancer. 2019 Jan 8;18(1):4. doi: 10.1186/s12943-018-0933-7.
|
| 86 |
Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles.Nanomedicine. 2020 Feb;24:102124. doi: 10.1016/j.nano.2019.102124. Epub 2019 Nov 20.
|
| 87 |
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.Cancer Res. 2020 Feb 1;80(3):444-457. doi: 10.1158/0008-5472.CAN-19-1108. Epub 2019 Nov 13.
|
| 88 |
Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.Cell Rep. 2018 Apr 3;23(1):112-126. doi: 10.1016/j.celrep.2018.03.039.
|
| 89 |
Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer.Stem Cells Int. 2017;2017:5091541. doi: 10.1155/2017/5091541. Epub 2017 Mar 14.
|
| 90 |
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.Cancer Cell. 2019 Nov 11;36(5):545-558.e7. doi: 10.1016/j.ccell.2019.09.004. Epub 2019 Oct 24.
|
| 91 |
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.
|
| 92 |
A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.Breast Cancer Res. 2019 Jul 1;21(1):77. doi: 10.1186/s13058-019-1161-9.
|
| 93 |
Intense dose-dense epirubicin, paclitaxel, cyclophosphamideversus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5.
|
| 94 |
DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.Cancer Lett. 2019 Feb 1;442:242-251. doi: 10.1016/j.canlet.2018.11.003. Epub 2018 Nov 9.
|
| 95 |
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24881-24891. doi: 10.1073/pnas.1912033116. Epub 2019 Nov 21.
|
| 96 |
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.Nat Commun. 2019 Nov 15;10(1):5177. doi: 10.1038/s41467-019-13168-4.
|
| 97 |
Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer.Pathobiology. 2019;86(5-6):315-321. doi: 10.1159/000503311. Epub 2019 Nov 8.
|
| 98 |
Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells.Cancers (Basel). 2019 Jan 17;11(1):105. doi: 10.3390/cancers11010105.
|
| 99 |
The orphan nuclear receptor estrogen-related receptor beta (ERR) in triple-negative breast cancer.Breast Cancer Res Treat. 2020 Feb;179(3):585-604. doi: 10.1007/s10549-019-05485-5. Epub 2019 Nov 19.
|
| 100 |
A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer.Oncotarget. 2016 Apr 5;7(14):18984-98. doi: 10.18632/oncotarget.7920.
|
| 101 |
miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.PLoS One. 2017 Apr 24;12(4):e0176395. doi: 10.1371/journal.pone.0176395. eCollection 2017.
|
| 102 |
Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.Breast Cancer Res. 2019 Oct 22;21(1):116. doi: 10.1186/s13058-019-1205-1.
|
| 103 |
FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.J Mol Med (Berl). 2019 Apr;97(4):491-508. doi: 10.1007/s00109-019-01750-8. Epub 2019 Feb 7.
|
| 104 |
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin.J Breast Cancer. 2019 Mar;22(1):141-148. doi: 10.4048/jbc.2019.22.e2.
|
| 105 |
BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.Breast Cancer Res. 2018 Oct 1;20(1):117. doi: 10.1186/s13058-018-1046-3.
|
| 106 |
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.J Cell Physiol. 2020 Mar;235(3):2631-2642. doi: 10.1002/jcp.29167. Epub 2019 Sep 11.
|
| 107 |
Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.Bioorg Med Chem. 2019 Apr 1;27(7):1370-1381. doi: 10.1016/j.bmc.2019.02.040. Epub 2019 Feb 20.
|
| 108 |
Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
|
| 109 |
The relationship between nuclear factor (NF)-B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.Sci Rep. 2016 Aug 22;6:31804. doi: 10.1038/srep31804.
|
| 110 |
Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/-catenin pathway.Neoplasma. 2019 Mar 5;66(2):232-239. doi: 10.4149/neo_2018_180710N460. Epub 2018 Sep 29.
|
| 111 |
In vivo -catenin attenuation by the integrin 5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.Biomaterials. 2019 Jan;188:160-172. doi: 10.1016/j.biomaterials.2018.10.019. Epub 2018 Oct 18.
|
| 112 |
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.J Exp Clin Cancer Res. 2019 Jan 11;38(1):16. doi: 10.1186/s13046-018-0999-5.
|
| 113 |
Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer.Front Immunol. 2019 Jun 12;10:1351. doi: 10.3389/fimmu.2019.01351. eCollection 2019.
|
| 114 |
KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells.Oncotarget. 2019 Jul 30;10(46):4743-4760. doi: 10.18632/oncotarget.27092. eCollection 2019 Jul 30.
|
| 115 |
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.Sci Rep. 2019 Nov 27;9(1):17663. doi: 10.1038/s41598-019-54184-0.
|
| 116 |
KiSS1 gene as a novel mediator of TGF-mediated cell invasion in triple negative breast cancer.Cell Signal. 2018 Jan;42:1-10. doi: 10.1016/j.cellsig.2017.10.002. Epub 2017 Oct 6.
|
| 117 |
The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.Oncotarget. 2017 Jul 12;8(49):85276-85289. doi: 10.18632/oncotarget.19205. eCollection 2017 Oct 17.
|
| 118 |
Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1(-)/FOXM1(+) Triple Negative Breast Cancer Cells.Mol Pharm. 2019 May 6;16(5):1813-1826. doi: 10.1021/acs.molpharmaceut.8b01065. Epub 2019 Mar 29.
|
| 119 |
Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14.
|
| 120 |
TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis.Nat Commun. 2018 May 18;9(1):1994. doi: 10.1038/s41467-018-04460-w.
|
| 121 |
The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.J Biol Chem. 2018 Dec 28;293(52):20014-20028. doi: 10.1074/jbc.RA118.005796. Epub 2018 Nov 15.
|
| 122 |
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9.
|
| 123 |
The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.Cancers (Basel). 2019 Mar 3;11(3):299. doi: 10.3390/cancers11030299.
|
| 124 |
MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259. Epub 2019 Mar 1.
|
| 125 |
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.J Pathol. 2018 Feb;244(2):143-150. doi: 10.1002/path.5006. Epub 2017 Dec 28.
|
| 126 |
Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes.Cancers (Basel). 2018 Oct 22;10(10):390. doi: 10.3390/cancers10100390.
|
| 127 |
Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.Mol Cancer Res. 2017 Jun;15(6):670-682. doi: 10.1158/1541-7786.MCR-16-0411. Epub 2017 Feb 24.
|
| 128 |
Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.Oncogene. 2014 May 1;33(18):2375-84. doi: 10.1038/onc.2013.183. Epub 2013 May 27.
|
| 129 |
Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.BMC Genomics. 2019 Feb 21;20(1):152. doi: 10.1186/s12864-019-5523-6.
|
| 130 |
Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.Oncotarget. 2017 Apr 29;8(33):54364-54377. doi: 10.18632/oncotarget.17532. eCollection 2017 Aug 15.
|
| 131 |
A versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring of triple negative breast cancer.Nanomedicine. 2020 Feb;24:102120. doi: 10.1016/j.nano.2019.102120. Epub 2019 Oct 30.
|
| 132 |
LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer.J Cell Mol Med. 2019 Jul;23(7):4738-4745. doi: 10.1111/jcmm.14344. Epub 2019 May 6.
|
| 133 |
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.Cancer Immunol Immunother. 2020 Jan;69(1):43-55. doi: 10.1007/s00262-019-02437-2. Epub 2019 Dec 3.
|
| 134 |
Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.Clin Exp Metastasis. 2020 Feb;37(1):187-197. doi: 10.1007/s10585-019-10000-7. Epub 2019 Oct 19.
|
| 135 |
A uPAR targeted nanoplatform with an NIR laser-responsive drug release property for tri-modal imaging and synergistic photothermal-chemotherapy of triple-negative breast cancer.Biomater Sci. 2020 Jan 21;8(2):720-738. doi: 10.1039/c9bm01495k.
|
| 136 |
Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.Int J Cancer. 2020 Jan 1;146(1):123-136. doi: 10.1002/ijc.32410. Epub 2019 May 31.
|
| 137 |
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.Cancer Res. 2016 Mar 15;76(6):1653-63. doi: 10.1158/0008-5472.CAN-15-2510. Epub 2016 Jan 29.
|
| 138 |
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.Cancer Res. 2016 Apr 1;76(7):1942-53. doi: 10.1158/0008-5472.CAN-14-0673. Epub 2016 Feb 26.
|
| 139 |
MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer.J Histochem Cytochem. 2020 Jan;68(1):25-32. doi: 10.1369/0022155419892965. Epub 2019 Dec 1.
|
| 140 |
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.J Hematol Oncol. 2019 Feb 8;12(1):14. doi: 10.1186/s13045-019-0700-2.
|
| 141 |
MiR-145 promotes TNF--induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer.Tumour Biol. 2016 Jul;37(7):8599-607. doi: 10.1007/s13277-015-4631-4. Epub 2016 Jan 6.
|
| 142 |
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.Cancer Res. 2018 Apr 1;78(7):1845-1858. doi: 10.1158/0008-5472.CAN-17-2388. Epub 2018 Jan 22.
|
| 143 |
The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms.Int J Cancer. 2018 Jun 15;142(12):2529-2542. doi: 10.1002/ijc.31276. Epub 2018 Feb 7.
|
| 144 |
Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells.J Biol Chem. 2019 Mar 15;294(11):4012-4026. doi: 10.1074/jbc.RA118.006378. Epub 2019 Jan 11.
|
| 145 |
Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells.Cancer Sci. 2019 Oct;110(10):3173-3182. doi: 10.1111/cas.14181. Epub 2019 Oct 3.
|
| 146 |
Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.Int J Nanomedicine. 2018 Nov 20;13:7771-7787. doi: 10.2147/IJN.S187089. eCollection 2018.
|
| 147 |
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.Cancer Res. 2016 Feb 15;76(4):927-39. doi: 10.1158/0008-5472.CAN-15-2321. Epub 2015 Dec 16.
|
| 148 |
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.BMC Cancer. 2019 Jan 21;19(1):96. doi: 10.1186/s12885-019-5290-4.
|
| 149 |
TDP-43 is Required for Mammary Gland Repopulation and Proliferation of Mammary Epithelial Cells.Stem Cells Dev. 2019 Jul 15;28(14):944-953. doi: 10.1089/scd.2019.0011. Epub 2019 Jun 11.
|
| 150 |
Phosphorylation of RAB7 by TBK1/IKK Regulates Innate Immune Signaling in Triple-Negative Breast Cancer.Cancer Res. 2020 Jan 1;80(1):44-56. doi: 10.1158/0008-5472.CAN-19-1310. Epub 2019 Oct 29.
|
| 151 |
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.Int J Cancer. 2013 Nov 15;133(10):2334-40. doi: 10.1002/ijc.28254. Epub 2013 Jun 4.
|
| 152 |
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.Cell Death Dis. 2019 Mar 28;10(4):285. doi: 10.1038/s41419-019-1512-6.
|
| 153 |
Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells.Mol Ther Nucleic Acids. 2019 Sep 6;17:24-37. doi: 10.1016/j.omtn.2019.05.003. Epub 2019 May 18.
|
| 154 |
Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo.Cancer Prev Res (Phila). 2019 Mar;12(3):147-158. doi: 10.1158/1940-6207.CAPR-18-0241. Epub 2019 Jan 24.
|
| 155 |
miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.J BUON. 2019 Sep-Oct;24(5):1905-1912.
|
| 156 |
Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer.Sci Rep. 2017 Mar 15;7:44414. doi: 10.1038/srep44414.
|
| 157 |
miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.Breast Cancer Res. 2016 Apr 2;18(1):40. doi: 10.1186/s13058-016-0699-z.
|
| 158 |
Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling.Oncotarget. 2018 Oct 2;9(77):34554-34566. doi: 10.18632/oncotarget.26177. eCollection 2018 Oct 2.
|
| 159 |
Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.Cancer Sci. 2013 May;104(5):639-46. doi: 10.1111/cas.12121. Epub 2013 Mar 15.
|
| 160 |
Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.Int J Mol Sci. 2019 Aug 27;20(17):4197. doi: 10.3390/ijms20174197.
|
| 161 |
ANXA2 expression in African American triple-negative breast cancer patients.Breast Cancer Res Treat. 2019 Feb;174(1):113-120. doi: 10.1007/s10549-018-5030-5. Epub 2018 Nov 26.
|
| 162 |
Expression of AQP3 and AQP5 as a prognostic marker in triple-negative breast cancer.Oncol Lett. 2018 Aug;16(2):2661-2667. doi: 10.3892/ol.2018.8955. Epub 2018 Jun 12.
|
| 163 |
ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions.Cell Signal. 2015 Mar;27(3):403-15. doi: 10.1016/j.cellsig.2014.11.032. Epub 2014 Dec 19.
|
| 164 |
Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNAdamaging chemotherapy agents and radiation.Oncol Rep. 2020 Jan;43(1):318-327. doi: 10.3892/or.2019.7418. Epub 2019 Nov 27.
|
| 165 |
A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.Autophagy. 2019 Aug;15(8):1376-1390. doi: 10.1080/15548627.2019.1582951. Epub 2019 Mar 1.
|
| 166 |
AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.Oncotarget. 2019 Mar 12;10(21):2055-2067. doi: 10.18632/oncotarget.26725. eCollection 2019 Mar 12.
|
| 167 |
Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study.Front Oncol. 2019 May 7;9:354. doi: 10.3389/fonc.2019.00354. eCollection 2019.
|
| 168 |
Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.Cell Death Dis. 2018 Jan 26;9(2):137. doi: 10.1038/s41419-017-0169-2.
|
| 169 |
Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes.J Biol Chem. 2018 Feb 9;293(6):2125-2136. doi: 10.1074/jbc.M117.811463. Epub 2017 Dec 20.
|
| 170 |
BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.Mol Cancer Res. 2018 Apr;16(4):580-586. doi: 10.1158/1541-7786.MCR-17-0568. Epub 2018 Feb 7.
|
| 171 |
Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.Mol Biol Rep. 2018 Oct;45(5):1413-1419. doi: 10.1007/s11033-018-4307-4. Epub 2018 Aug 22.
|
| 172 |
Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.Oncogene. 2019 Jan;38(3):390-405. doi: 10.1038/s41388-018-0451-5. Epub 2018 Aug 15.
|
| 173 |
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.Sci Rep. 2017 Feb 8;7:42319. doi: 10.1038/srep42319.
|
| 174 |
Ecotropic virus integration-1 and calreticulin as novel prognostic markers in triple-negative breast cancer: A retrospective cohort study.Oncol Lett. 2019 Aug;18(2):1847-1855. doi: 10.3892/ol.2019.10472. Epub 2019 Jun 12.
|
| 175 |
Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns.Cancer Genomics Proteomics. 2013 Nov-Dec;10(6):265-75.
|
| 176 |
Cdc20 and securin overexpression predict short-term breast cancer survival.Br J Cancer. 2014 Jun 10;110(12):2905-13. doi: 10.1038/bjc.2014.252. Epub 2014 May 22.
|
| 177 |
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.Tumour Biol. 2015 Jul;36(7):5001-9. doi: 10.1007/s13277-015-3151-6. Epub 2015 Feb 14.
|
| 178 |
Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.Cancer Sci. 2018 Oct;109(10):3272-3284. doi: 10.1111/cas.13748. Epub 2018 Aug 26.
|
| 179 |
The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.Cell Physiol Biochem. 2019;52(3):382-396. doi: 10.33594/000000027. Epub 2019 Mar 8.
|
| 180 |
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.
|
| 181 |
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.Clin Cancer Res. 2018 Dec 15;24(24):6594-6610. doi: 10.1158/1078-0432.CCR-18-1446. Epub 2018 Sep 4.
|
| 182 |
Antitumor Activity of Vanicoside B Isolated from Persicaria dissitiflora by Targeting CDK8 in Triple-Negative Breast Cancer Cells.J Nat Prod. 2019 Nov 22;82(11):3140-3149. doi: 10.1021/acs.jnatprod.9b00720. Epub 2019 Oct 17.
|
| 183 |
Increasing intratumor C/EBP- LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.
|
| 184 |
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577. doi: 10.1073/pnas.1719577115. Epub 2018 Jan 29.
|
| 185 |
Notch Signaling Regulates Mitochondrial Metabolism and NF-B Activity in Triple-Negative Breast Cancer Cells via IKK-Dependent Non-canonical Pathways.Front Oncol. 2018 Dec 4;8:575. doi: 10.3389/fonc.2018.00575. eCollection 2018.
|
| 186 |
CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.Mol Cell Biochem. 2018 Jun;443(1-2):169-180. doi: 10.1007/s11010-017-3221-8. Epub 2017 Nov 20.
|
| 187 |
Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G(1)-S Checkpoint.Mol Cancer Ther. 2018 Aug;17(8):1727-1738. doi: 10.1158/1535-7163.MCT-17-1084. Epub 2018 Jun 4.
|
| 188 |
MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.Mol Cancer. 2019 Mar 18;18(1):42. doi: 10.1186/s12943-019-0988-0.
|
| 189 |
MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.Cancer Lett. 2019 Nov 28;465:12-23. doi: 10.1016/j.canlet.2019.08.016. Epub 2019 Aug 29.
|
| 190 |
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16.
|
| 191 |
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.Photochem Photobiol Sci. 2018 May 16;17(5):539-551. doi: 10.1039/C7PP00358G.
|
| 192 |
A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer.J Oncol. 2019 Jun 27;2019:3980273. doi: 10.1155/2019/3980273. eCollection 2019.
|
| 193 |
CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer.Cancer Biother Radiopharm. 2018 Apr;33(3):87-95. doi: 10.1089/cbr.2017.2376.
|
| 194 |
Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.Breast Cancer Res Treat. 2015 Feb;150(1):9-18. doi: 10.1007/s10549-015-3285-7. Epub 2015 Feb 10.
|
| 195 |
DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer.Oncotarget. 2017 Oct 17;8(58):98708-98722. doi: 10.18632/oncotarget.21864. eCollection 2017 Nov 17.
|
| 196 |
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition.Oncotarget. 2017 Jul 12;8(56):95206-95222. doi: 10.18632/oncotarget.19199. eCollection 2017 Nov 10.
|
| 197 |
miR-221/222 activate the Wnt/-catenin signaling to promote triple-negative breast cancer.J Mol Cell Biol. 2018 Aug 1;10(4):302-315. doi: 10.1093/jmcb/mjy041.
|
| 198 |
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.Mol Ther Oncolytics. 2019 Oct 1;15:140-152. doi: 10.1016/j.omto.2019.09.005. eCollection 2019 Dec 20.
|
| 199 |
MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.Cell Physiol Biochem. 2018;48(2):593-604. doi: 10.1159/000491888. Epub 2018 Jul 18.
|
| 200 |
PERK-Phosphorylated eIF2 Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.Cancer Biother Radiopharm. 2017 Oct;32(8):282-287. doi: 10.1089/cbr.2017.2237.
|
| 201 |
MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.Oncol Lett. 2019 Dec;18(6):5986-5994. doi: 10.3892/ol.2019.10984. Epub 2019 Oct 14.
|
| 202 |
MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.Mol Cancer Ther. 2017 Jan;16(1):143-155. doi: 10.1158/1535-7163.MCT-16-0413. Epub 2016 Nov 3.
|
| 203 |
miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.Carcinogenesis. 2015 Sep;36(9):1051-60. doi: 10.1093/carcin/bgv087. Epub 2015 Jun 18.
|
| 204 |
EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.Oncogene. 2018 Jul;37(30):4073-4093. doi: 10.1038/s41388-018-0228-x. Epub 2018 Apr 27.
|
| 205 |
CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer.Biomater Sci. 2019 Dec 17;8(1):212-223. doi: 10.1039/c9bm01171d.
|
| 206 |
STAT3 Targets ERR- to Promote Epithelial-Mesenchymal Transition, Migration, and Invasion in Triple-Negative Breast Cancer Cells.Mol Cancer Res. 2019 Nov;17(11):2184-2195. doi: 10.1158/1541-7786.MCR-18-1194. Epub 2019 Aug 19.
|
| 207 |
Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models.Anticancer Res. 2019 Mar;39(3):1197-1204. doi: 10.21873/anticanres.13230.
|
| 208 |
Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3426-E3435. doi: 10.1073/pnas.1714573115. Epub 2018 Mar 26.
|
| 209 |
FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.Theranostics. 2019 Sep 21;9(23):7003-7015. doi: 10.7150/thno.35561. eCollection 2019.
|
| 210 |
Inhibition of the AnxA1/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo.Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1368-1382. doi: 10.1016/j.bbamcr.2018.06.010. Epub 2018 Jun 20.
|
| 211 |
A piRNA utilizes HILI and HIWI2 mediated pathway to down-regulate ferritin heavy chain 1 mRNA in human somatic cells.Nucleic Acids Res. 2018 Nov 16;46(20):10635-10648. doi: 10.1093/nar/gky728.
|
| 212 |
Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.
|
| 213 |
A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1-XBP1 Activation.Mol Cancer Res. 2018 May;16(5):745-753. doi: 10.1158/1541-7786.MCR-17-0307. Epub 2018 Feb 9.
|
| 214 |
Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells.Oncotarget. 2019 Mar 19;10(23):2292-2305. doi: 10.18632/oncotarget.26765. eCollection 2019 Mar 19.
|
| 215 |
Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis.Sci Rep. 2019 Dec 16;9(1):19150. doi: 10.1038/s41598-019-55702-w.
|
| 216 |
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.Sci Signal. 2017 Apr 11;10(474):eaak9397. doi: 10.1126/scisignal.aak9397.
|
| 217 |
G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion.Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4191-6. doi: 10.1073/pnas.1320239111. Epub 2014 Mar 5.
|
| 218 |
G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis.PLoS One. 2016 Apr 6;11(4):e0152856. doi: 10.1371/journal.pone.0152856. eCollection 2016.
|
| 219 |
Downregulation of GRK5 hampers the migration of breast cancer cells.Sci Rep. 2019 Oct 29;9(1):15548. doi: 10.1038/s41598-019-51923-1.
|
| 220 |
Clinical Implications of Extracellular HMGA1 in Breast Cancer.Int J Mol Sci. 2019 Nov 26;20(23):5950. doi: 10.3390/ijms20235950.
|
| 221 |
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.Mol Oncol. 2019 Feb;13(2):153-170. doi: 10.1002/1878-0261.12390. Epub 2018 Nov 28.
|
| 222 |
IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.Cell Mol Life Sci. 2019 May;76(10):2015-2030. doi: 10.1007/s00018-019-03033-4. Epub 2019 Feb 6.
|
| 223 |
Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.Biomed Pharmacother. 2018 Nov;107:1064-1073. doi: 10.1016/j.biopha.2018.07.099. Epub 2018 Aug 25.
|
| 224 |
IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.Cancer Lett. 2018 Feb 28;415:30-39. doi: 10.1016/j.canlet.2017.11.039. Epub 2017 Dec 5.
|
| 225 |
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746.
|
| 226 |
Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6008-6014. doi: 10.26355/eurrev_201809_15936.
|
| 227 |
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.Breast Cancer (Auckl). 2018 Jul 27;12:1178223418773075. doi: 10.1177/1178223418773075. eCollection 2018.
|
| 228 |
Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.Angew Chem Int Ed Engl. 2018 Oct 1;57(40):13091-13095. doi: 10.1002/anie.201807305. Epub 2018 Jul 19.
|
| 229 |
KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells.Oncotarget. 2017 Sep 8;8(54):92106-92118. doi: 10.18632/oncotarget.20785. eCollection 2017 Nov 3.
|
| 230 |
Klotho is a novel marker and cell survival factor in a subset of triple negative breast cancers.Oncotarget. 2016 Jan 19;7(3):2611-28. doi: 10.18632/oncotarget.6006.
|
| 231 |
Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.Biol Chem. 2017 Sep 26;398(10):1151-1164. doi: 10.1515/hsz-2017-0122.
|
| 232 |
Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course.Genet Mol Res. 2015 Aug 14;14(3):9655-66. doi: 10.4238/2015.August.14.28.
|
| 233 |
The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.Int Immunopharmacol. 2020 Jan;78:106113. doi: 10.1016/j.intimp.2019.106113. Epub 2019 Dec 13.
|
| 234 |
HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.
|
| 235 |
LGR5 overexpression confers poor relapse-free survival in breast cancer patients.BMC Cancer. 2018 Feb 22;18(1):219. doi: 10.1186/s12885-018-4018-1.
|
| 236 |
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.
|
| 237 |
LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer.Elife. 2018 Jan 19;7:e31334. doi: 10.7554/eLife.31334.
|
| 238 |
PIM-1 kinase: a potential biomarker of triple-negative breast cancer.Onco Targets Ther. 2019 Aug 8;12:6267-6273. doi: 10.2147/OTT.S212752. eCollection 2019.
|
| 239 |
The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.J Oncol. 2019 Mar 26;2019:4536302. doi: 10.1155/2019/4536302. eCollection 2019.
|
| 240 |
BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer.BMB Rep. 2018 Aug;51(8):373-377. doi: 10.5483/bmbrep.2018.51.8.127.
|
| 241 |
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther. 2019 Sep;18(9):1533-1543.
|
| 242 |
hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.Oncotarget. 2017 Jun 6;8(23):37115-37127. doi: 10.18632/oncotarget.16184.
|
| 243 |
Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.Int J Mol Sci. 2017 Dec 20;18(12):2775. doi: 10.3390/ijms18122775.
|
| 244 |
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.
|
| 245 |
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.J Cell Biochem. 2020 Feb;121(2):1156-1168. doi: 10.1002/jcb.29350. Epub 2019 Aug 28.
|
| 246 |
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.Oncogenesis. 2017 Jun 12;6(6):e345. doi: 10.1038/oncsis.2017.44.
|
| 247 |
Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.Biochem Biophys Res Commun. 2017 Jan 29;483(1):10-16. doi: 10.1016/j.bbrc.2017.01.023. Epub 2017 Jan 7.
|
| 248 |
Expression of MAS1 in breast cancer.Cancer Sci. 2015 Sep;106(9):1240-8. doi: 10.1111/cas.12719. Epub 2015 Jul 20.
|
| 249 |
The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways.Cell Calcium. 2019 May;79:80-88. doi: 10.1016/j.ceca.2019.02.010. Epub 2019 Mar 2.
|
| 250 |
MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.Oncol Lett. 2018 Jun;15(6):9934-9940. doi: 10.3892/ol.2018.8543. Epub 2018 Apr 20.
|
| 251 |
MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer.Cancer Gene Ther. 2016 Aug;23(8):258-65. doi: 10.1038/cgt.2016.27. Epub 2016 Jul 1.
|
| 252 |
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.Clin Cancer Res. 2019 Mar 15;25(6):1838-1850. doi: 10.1158/1078-0432.CCR-18-1880. Epub 2018 Nov 30.
|
| 253 |
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.Cancer Immunol Immunother. 2019 Mar;68(3):365-377. doi: 10.1007/s00262-018-2281-2. Epub 2018 Dec 6.
|
| 254 |
RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.Mol Cancer Ther. 2018 Dec;17(12):2654-2664. doi: 10.1158/1535-7163.MCT-18-0252. Epub 2018 Oct 1.
|
| 255 |
Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway.Biochem Biophys Res Commun. 2018 Nov 10;505(4):996-1002. doi: 10.1016/j.bbrc.2018.10.026. Epub 2018 Oct 9.
|
| 256 |
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.PLoS One. 2015 Mar 24;10(3):e0118854. doi: 10.1371/journal.pone.0118854. eCollection 2015.
|
| 257 |
Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.Front Med (Lausanne). 2019 Sep 13;6:200. doi: 10.3389/fmed.2019.00200. eCollection 2019.
|
| 258 |
YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein.Biochem Biophys Res Commun. 2019 Feb 5;509(2):448-454. doi: 10.1016/j.bbrc.2018.12.074. Epub 2018 Dec 26.
|
| 259 |
Expression of Nischarin negatively correlates with estrogen receptor and alters apoptosis, migration and invasion in human breast cancer. Biochem Biophys Res Commun. 2017 Mar 11;484(3):536-542.
|
| 260 |
Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway.Cancer Manag Res. 2018 Dec 21;11:143-156. doi: 10.2147/CMAR.S191176. eCollection 2019.
|
| 261 |
Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration.Pharmacol Res. 2019 May;143:17-26. doi: 10.1016/j.phrs.2019.03.008. Epub 2019 Mar 9.
|
| 262 |
The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14174-14180. doi: 10.1073/pnas.1821194116. Epub 2019 Jun 24.
|
| 263 |
Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.Nanomedicine (Lond). 2018 May;13(9):1051-1066. doi: 10.2217/nnm-2017-0328. Epub 2018 May 23.
|
| 264 |
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1 stabilization and TNBC chemoresistance.Nat Commun. 2018 Oct 26;9(1):4456. doi: 10.1038/s41467-018-06893-9.
|
| 265 |
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555.
|
| 266 |
Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer.Dev Cell. 2017 Nov 20;43(4):418-435.e13. doi: 10.1016/j.devcel.2017.10.027.
|
| 267 |
Blockade of PDGFR circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltrationin triple-negative breast cancer.J Exp Clin Cancer Res. 2019 Feb 18;38(1):85. doi: 10.1186/s13046-019-1075-5.
|
| 268 |
Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.Sci Rep. 2017 May 17;7(1):2022. doi: 10.1038/s41598-017-02222-0.
|
| 269 |
A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.Mol Cancer Res. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.
|
| 270 |
Targeting PML in triple negative breast cancer elicits growth suppression and senescence.Cell Death Differ. 2020 Apr;27(4):1186-1199. doi: 10.1038/s41418-019-0407-5. Epub 2019 Oct 1.
|
| 271 |
CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.Int J Cancer. 2019 Feb 1;144(3):631-640. doi: 10.1002/ijc.31798. Epub 2018 Nov 7.
|
| 272 |
Protein kinase C enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.BMC Cancer. 2017 Dec 7;17(1):832. doi: 10.1186/s12885-017-3827-y.
|
| 273 |
The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.Breast Cancer. 2018 Jan;25(1):74-80. doi: 10.1007/s12282-017-0790-z. Epub 2017 Jun 22.
|
| 274 |
PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.Int J Biol Markers. 2018 Jan;33(1):102-108. doi: 10.5301/ijbm.5000283.
|
| 275 |
Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.Bosn J Basic Med Sci. 2019 Feb 12;19(1):52-59. doi: 10.17305/bjbms.2018.3399.
|
| 276 |
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.Sci Transl Med. 2017 Jan 11;9(372):eaag2611. doi: 10.1126/scitranslmed.aag2611.
|
| 277 |
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/-catenin signaling.Biomed Pharmacother. 2019 Oct;118:109361. doi: 10.1016/j.biopha.2019.109361. Epub 2019 Aug 23.
|
| 278 |
Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-B pathway in breast cancer cells.Cell Commun Signal. 2018 Nov 29;16(1):92. doi: 10.1186/s12964-018-0304-4.
|
| 279 |
TUFT1 promotes metastasis and chemoresistance in triple negative breast cancer through the TUFT1/Rab5/Rac1 pathway.Cancer Cell Int. 2019 Sep 23;19:242. doi: 10.1186/s12935-019-0961-4. eCollection 2019.
|
| 280 |
cAMP regulated EPAC1 supports microvascular density, angiogenic and metastatic properties in a model of triple negative breast cancer.Carcinogenesis. 2018 Oct 8;39(10):1245-1253. doi: 10.1093/carcin/bgy090.
|
| 281 |
RIP2 enhances cell survival by activation of NF-B in triple negative breast cancer cells.Biochem Biophys Res Commun. 2018 Feb 26;497(1):115-121. doi: 10.1016/j.bbrc.2018.02.034. Epub 2018 Feb 6.
|
| 282 |
Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.BMB Rep. 2019 Dec;52(12):706-711. doi: 10.5483/BMBRep.2019.52.12.234.
|
| 283 |
Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer.Oncotarget. 2019 Jan 11;10(4):511-526. doi: 10.18632/oncotarget.26566. eCollection 2019 Jan 11.
|
| 284 |
Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.Oncotarget. 2017 Jul 10;8(35):59086-59102. doi: 10.18632/oncotarget.19175. eCollection 2017 Aug 29.
|
| 285 |
Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.Exp Cell Res. 2018 Sep 15;370(2):444-453. doi: 10.1016/j.yexcr.2018.07.008. Epub 2018 Jul 5.
|
| 286 |
Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins.Mar Drugs. 2018 Nov 10;16(11):442. doi: 10.3390/md16110442.
|
| 287 |
SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival.Mol Cell Biol. 2016 Nov 28;36(24):3048-3057. doi: 10.1128/MCB.00380-16. Print 2016 Dec 15.
|
| 288 |
SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
|
| 289 |
Deferoxamine-inducedhigh expression of TfR1 and DMT1 enhanced iron uptake intriple-negative breast cancer cells by activatingIL-6/PI3K/AKTpathway.Onco Targets Ther. 2019 May 31;12:4359-4377. doi: 10.2147/OTT.S193507. eCollection 2019.
|
| 290 |
Somatic gene mutation analysis of triple negative breast cancers.Breast. 2016 Oct;29:202-7. doi: 10.1016/j.breast.2016.06.018. Epub 2016 Jul 7.
|
| 291 |
"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.ACS Nano. 2015 Feb 24;9(2):1367-78. doi: 10.1021/nn505729m. Epub 2015 Jan 26.
|
| 292 |
SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity.Mol Oncol. 2019 Sep;13(9):1874-1886. doi: 10.1002/1878-0261.12530. Epub 2019 Jun 14.
|
| 293 |
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.
|
| 294 |
Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5.Exp Ther Med. 2018 May;15(5):4515-4521. doi: 10.3892/etm.2018.5945. Epub 2018 Mar 9.
|
| 295 |
Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.Sci Rep. 2016 Mar 15;6:23216. doi: 10.1038/srep23216.
|
| 296 |
The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1-/VEGF-signaling.Gynecol Endocrinol. 2015 Feb;31(2):160-4. doi: 10.3109/09513590.2014.971235. Epub 2014 Oct 30.
|
| 297 |
SRGN-TGF2 regulatory loop confers invasion and metastasis in triple-negative breast cancer.Oncogenesis. 2017 Jul 10;6(7):e360. doi: 10.1038/oncsis.2017.53.
|
| 298 |
Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.Biochem Biophys Res Commun. 2019 Feb 5;509(2):476-482. doi: 10.1016/j.bbrc.2018.12.145. Epub 2018 Dec 27.
|
| 299 |
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.
|
| 300 |
Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.
|
| 301 |
T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.Breast Cancer Res Treat. 2019 Aug;176(3):569-577. doi: 10.1007/s10549-019-05256-2. Epub 2019 May 8.
|
| 302 |
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.Mol Cancer Res. 2019 Jan;17(1):30-41. doi: 10.1158/1541-7786.MCR-18-0246. Epub 2018 Sep 13.
|
| 303 |
Targeting thyroid hormone receptor beta in triple-negative breast cancer.Breast Cancer Res Treat. 2015 Apr;150(3):535-45. doi: 10.1007/s10549-015-3354-y. Epub 2015 Mar 28.
|
| 304 |
Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the -Ketoglutarate Signaling Pathway.Cancer Res. 2018 Jun 1;78(11):2799-2812. doi: 10.1158/0008-5472.CAN-17-2906. Epub 2018 Mar 29.
|
| 305 |
Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer.Cytokine. 2020 Jan;125:154790. doi: 10.1016/j.cyto.2019.154790. Epub 2019 Aug 7.
|
| 306 |
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.
|
| 307 |
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.Oncotarget. 2017 Jan 10;8(2):2971-2983. doi: 10.18632/oncotarget.13579.
|
| 308 |
Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.Anticancer Res. 2018 Mar;38(3):1303-1310. doi: 10.21873/anticanres.12352.
|
| 309 |
miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2.Gene. 2016 Nov 15;593(1):41-47. doi: 10.1016/j.gene.2016.08.014. Epub 2016 Aug 6.
|
| 310 |
TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.Mol Carcinog. 2018 Dec;57(12):1792-1802. doi: 10.1002/mc.22897. Epub 2018 Sep 20.
|
| 311 |
The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature.Lab Invest. 2020 Feb;100(2):186-198. doi: 10.1038/s41374-019-0333-7. Epub 2019 Oct 25.
|
| 312 |
MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression.Sci Rep. 2019 Sep 3;9(1):12718. doi: 10.1038/s41598-019-49155-4.
|
| 313 |
Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.J Cell Mol Med. 2019 Mar;23(3):2194-2206. doi: 10.1111/jcmm.14139. Epub 2019 Jan 4.
|
| 314 |
A novel UCHL(3) inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair.Cell Death Dis. 2019 May 21;10(6):398. doi: 10.1038/s41419-019-1628-8.
|
| 315 |
Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo.Chem Sci. 2017 Apr 1;8(4):2687-2701. doi: 10.1039/c6sc05368h. Epub 2017 Jan 9.
|
| 316 |
B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer.Cancer Cell Int. 2018 Jul 13;18:100. doi: 10.1186/s12935-018-0597-9. eCollection 2018.
|
| 317 |
Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.J Cell Mol Med. 2019 May;23(5):3271-3279. doi: 10.1111/jcmm.14213. Epub 2019 Mar 1.
|
| 318 |
Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.PLoS One. 2012;7(10):e47993. doi: 10.1371/journal.pone.0047993. Epub 2012 Oct 24.
|
| 319 |
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.Breast Cancer. 2011 Apr;18(2):120-3. doi: 10.1007/s12282-009-0175-z. Epub 2009 Oct 8.
|
| 320 |
A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.Hum Pathol. 2019 Mar;85:221-227. doi: 10.1016/j.humpath.2018.11.005. Epub 2018 Nov 20.
|
| 321 |
MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.J Exp Clin Cancer Res. 2012 Jun 19;31(1):58. doi: 10.1186/1756-9966-31-58.
|
| 322 |
Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.Am J Pathol. 2012 Jul;181(1):257-67. doi: 10.1016/j.ajpath.2012.03.019. Epub 2012 May 21.
|
| 323 |
Role of nestin expression in angiogenesis and breast cancer progression.Int J Oncol. 2018 Feb;52(2):527-535. doi: 10.3892/ijo.2017.4223. Epub 2017 Dec 11.
|
| 324 |
miR-200c targets a NF-B up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer.PLoS One. 2012;7(11):e49987. doi: 10.1371/journal.pone.0049987. Epub 2012 Nov 21.
|
| 325 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.
|
| 326 |
Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.Med Oncol. 2013;30(3):612. doi: 10.1007/s12032-013-0612-x. Epub 2013 May 22.
|
| 327 |
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.Br J Cancer. 2014 Aug 12;111(4):696-707. doi: 10.1038/bjc.2014.326. Epub 2014 Jun 17.
|
| 328 |
Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma.BMC Cancer. 2018 Apr 27;18(1):477. doi: 10.1186/s12885-018-4381-y.
|
| 329 |
Novel key genes in triple-negative breast cancer identified by weighted gene co-expression network analysis.J Cell Biochem. 2019 Oct;120(10):16900-16912. doi: 10.1002/jcb.28948. Epub 2019 May 13.
|
| 330 |
HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.Cancer Res. 2014 Feb 1;74(3):862-72. doi: 10.1158/0008-5472.CAN-13-2420. Epub 2013 Dec 2.
|
| 331 |
The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.Oncotarget. 2015 May 10;6(13):11061-73. doi: 10.18632/oncotarget.3568.
|
| 332 |
The apple polyphenol phloretin inhibits breast cancer cell migration and proliferation via inhibition of signals by type 2 glucose transporter.J Food Drug Anal. 2018 Jan;26(1):221-231. doi: 10.1016/j.jfda.2017.03.009. Epub 2017 Apr 18.
|
| 333 |
Dual-targeting liposomes with active recognition of GLUT(5) and (v)(3) for triple-negative breast cancer.Eur J Med Chem. 2019 Dec 1;183:111720. doi: 10.1016/j.ejmech.2019.111720. Epub 2019 Sep 18.
|
| 334 |
Synthetic Indolactam V Analogues as Inhibitors of PAR2-Induced Calcium Mobilization in Triple-Negative Breast Cancer Cells.ChemMedChem. 2018 Jan 22;13(2):147-154. doi: 10.1002/cmdc.201700640. Epub 2018 Jan 4.
|
| 335 |
Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.Breast Cancer Res. 2018 Nov 28;20(1):145. doi: 10.1186/s13058-018-1068-x.
|
| 336 |
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11121-6.
|
| 337 |
Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.
|
| 338 |
Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.Int J Oncol. 2019 Mar;54(3):833-844. doi: 10.3892/ijo.2019.4675. Epub 2019 Jan 4.
|
| 339 |
LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women.Breast Cancer (Dove Med Press). 2018 Dec 20;11:1-12. doi: 10.2147/BCTT.S185960. eCollection 2019.
|
| 340 |
MAT2B expression correlates with poor prognosis in triple-negative breast cancer.Cancer Manag Res. 2019 Jun 14;11:5501-5511. doi: 10.2147/CMAR.S200716. eCollection 2019.
|
| 341 |
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.Cell Rep. 2014 Nov 20;9(4):1318-32. doi: 10.1016/j.celrep.2014.10.011. Epub 2014 Nov 6.
|
| 342 |
Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.Mol Cell Proteomics. 2015 Nov;14(11):2936-46. doi: 10.1074/mcp.M115.048967. Epub 2015 Jul 24.
|
| 343 |
Inherited predisposition to breast cancer among African American women.Breast Cancer Res Treat. 2015 Jan;149(1):31-9. doi: 10.1007/s10549-014-3195-0. Epub 2014 Nov 27.
|
| 344 |
ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.Cell Death Differ. 2020 Jan;27(1):363-378. doi: 10.1038/s41418-019-0362-1. Epub 2019 Jun 13.
|
| 345 |
Landscape of pathogenic variations ina panel of 34 genes and cancer risk estimation from 5131 HBOC families.Genet Med. 2018 Dec;20(12):1677-1686. doi: 10.1038/s41436-018-0005-9. Epub 2018 Jul 10.
|
| 346 |
BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
|
| 347 |
E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells.Clin Exp Med. 2020 Feb;20(1):109-119. doi: 10.1007/s10238-019-00594-3. Epub 2019 Dec 16.
|
| 348 |
H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis.Biomed Pharmacother. 2020 Mar;123:109728. doi: 10.1016/j.biopha.2019.109728. Epub 2019 Dec 14.
|
| 349 |
High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.BMC Cancer. 2018 Feb 27;18(1):223. doi: 10.1186/s12885-018-4141-z.
|
| 350 |
Half-sandwich Ru((6)-p-cymene) complexes featuring pyrazole appended ligands: Synthesis, DNA binding and in vitro cytotoxicity.J Inorg Biochem. 2019 May;194:74-84. doi: 10.1016/j.jinorgbio.2019.02.012. Epub 2019 Feb 23.
|
| 351 |
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
|
| 352 |
Weighted correlation network analysis of triple-negative breast cancer progression: Identifying specific modules and hub genes based on the GEO and TCGA database.Oncol Lett. 2019 Aug;18(2):1207-1217. doi: 10.3892/ol.2019.10407. Epub 2019 May 27.
|
| 353 |
Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ER Signaling Pathway in High-level MZF1-expressing TNBC cells.Anticancer Res. 2019 Aug;39(8):4149-4164. doi: 10.21873/anticanres.13574.
|
| 354 |
Cancer-associated oxidoreductase ERO1- promotes immune escape through up-regulation of PD-L1 in human breast cancer.Oncotarget. 2017 Apr 11;8(15):24706-24718. doi: 10.18632/oncotarget.14960.
|
| 355 |
Robust identification of target genes and outliers in triple-negative breast cancer data.Stat Methods Med Res. 2019 Oct-Nov;28(10-11):3042-3056. doi: 10.1177/0962280218794722. Epub 2018 Aug 27.
|
| 356 |
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29.
|
| 357 |
Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):1-5. doi: 10.1097/PAI.0000000000000622.
|
| 358 |
GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer.Biomed Pharmacother. 2016 Dec;84:1568-1574. doi: 10.1016/j.biopha.2016.10.032. Epub 2016 Nov 6.
|
| 359 |
Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: A STROBE-compliant article.Medicine (Baltimore). 2019 Mar;98(9):e14744. doi: 10.1097/MD.0000000000014744.
|
| 360 |
Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.Mol Oncol. 2019 Apr;13(4):959-977. doi: 10.1002/1878-0261.12466. Epub 2019 Mar 1.
|
| 361 |
Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.Breast Cancer Res Treat. 2014 Feb;143(3):593-603. doi: 10.1007/s10549-014-2838-5. Epub 2014 Jan 25.
|
| 362 |
Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.Breast Cancer Res. 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.
|
| 363 |
A novel biomarker C6orf106 promotes the malignant progression of breast cancer.Tumour Biol. 2015 Sep;36(10):7881-9. doi: 10.1007/s13277-015-3500-5. Epub 2015 May 8.
|
| 364 |
ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.Int J Mol Med. 2018 Nov;42(5):2343-2352. doi: 10.3892/ijmm.2018.3842. Epub 2018 Aug 27.
|
| 365 |
Integrin 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.Oncogene. 2013 Jun 20;32(25):3049-58. doi: 10.1038/onc.2012.320. Epub 2012 Jul 23.
|
| 366 |
JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity.Oncogene. 2019 Feb;38(7):980-997. doi: 10.1038/s41388-018-0466-y. Epub 2018 Sep 5.
|
| 367 |
Bio-Field Array: The Influence of Junction Mediating and Regulatory Protein Expression on Cytoskeletal Filament Behavior During Apoptosis in Triple-Negative Breast Cancer.Breast Cancer (Auckl). 2019 Feb 28;13:1178223419830981. doi: 10.1177/1178223419830981. eCollection 2019.
|
| 368 |
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.Breast Cancer Res Treat. 2018 Aug;171(1):43-52. doi: 10.1007/s10549-018-4815-x. Epub 2018 May 11.
|
| 369 |
Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krppel-like factor 5 transcription by Sp1.Sci Rep. 2018 Jan 18;8(1):1138. doi: 10.1038/s41598-018-19489-6.
|
| 370 |
Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.Breast Cancer (Dove Med Press). 2018 Nov 23;10:177-194. doi: 10.2147/BCTT.S175556. eCollection 2018.
|
| 371 |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1338-1352. doi: 10.1016/j.bbamcr.2019.03.010. Epub 2019 Mar 21.
|
| 372 |
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.Hum Genomics. 2019 Jan 10;13(1):4. doi: 10.1186/s40246-018-0186-y.
|
| 373 |
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.Mol Cancer Res. 2014 Sep;12(9):1216-24. doi: 10.1158/1541-7786.MCR-14-0069. Epub 2014 May 27.
|
| 374 |
Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.Oncogene. 2017 Apr;36(15):2116-2130. doi: 10.1038/onc.2016.369. Epub 2016 Oct 24.
|
| 375 |
NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.BMC Cancer. 2019 Apr 2;19(1):236. doi: 10.1186/s12885-019-5407-9.
|
| 376 |
Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions.PLoS One. 2019 Feb 14;14(2):e0211737. doi: 10.1371/journal.pone.0211737. eCollection 2019.
|
| 377 |
Tumor-Targeting Micelles Based on Linear-Dendritic PEG-PTX(8) Conjugate for Triple Negative Breast Cancer Therapy.Mol Pharm. 2017 Oct 2;14(10):3409-3421. doi: 10.1021/acs.molpharmaceut.7b00430. Epub 2017 Aug 30.
|
| 378 |
-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling.Oncogene. 2019 Jun;38(24):4856-4874. doi: 10.1038/s41388-019-0762-1. Epub 2019 Feb 25.
|
| 379 |
PDLIM2 Is a Marker of Adhesion and -Catenin Activity in Triple-Negative Breast Cancer.Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158/0008-5472.CAN-18-2787. Epub 2019 Mar 18.
|
| 380 |
Circulating noncoding RNAbiomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?.Int J Oncol. 2020 Jan;56(1):47-68. doi: 10.3892/ijo.2019.4920. Epub 2019 Nov 25.
|
| 381 |
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.Breast Cancer Res. 2019 Feb 21;21(1):29. doi: 10.1186/s13058-019-1107-2.
|
| 382 |
(99m)Tc-Labeled LyP-1 for SPECT Imaging of Triple Negative Breast Cancer.Contrast Media Mol Imaging. 2019 Sep 25;2019:9502712. doi: 10.1155/2019/9502712. eCollection 2019.
|
| 383 |
RPLP1 promotes tumor metastasis and is associated with a poor prognosis in triple-negative breast cancer patients.Cancer Cell Int. 2018 Oct 25;18:170. doi: 10.1186/s12935-018-0658-0. eCollection 2018.
|
| 384 |
SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin.J Cell Physiol. 2020 Feb;235(2):1543-1555. doi: 10.1002/jcp.29073. Epub 2019 Jul 17.
|
| 385 |
Activating Transcription Factor 4 Modulates TGF-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.Clin Cancer Res. 2018 Nov 15;24(22):5697-5709. doi: 10.1158/1078-0432.CCR-17-3125. Epub 2018 Jul 16.
|
| 386 |
An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer.Cell Death Differ. 2018 Dec;25(12):2209-2220. doi: 10.1038/s41418-018-0123-6. Epub 2018 May 29.
|
| 387 |
SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.Carcinogenesis. 2019 Oct 16;40(10):1278-1287. doi: 10.1093/carcin/bgz034.
|
| 388 |
CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid.Mol Cancer. 2015 Jul 5;14:129. doi: 10.1186/s12943-015-0380-7.
|
| 389 |
Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-/SMAD signaling.Oncotarget. 2015 Jun 30;6(18):16352-65. doi: 10.18632/oncotarget.3877.
|
| 390 |
Regulatory mechanisms leading to differential Acyl-CoA synthetase 4 expression in breast cancer cells.Sci Rep. 2019 Jul 16;9(1):10324. doi: 10.1038/s41598-019-46776-7.
|
| 391 |
Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12.PLoS One. 2014 Mar 20;9(3):e92536. doi: 10.1371/journal.pone.0092536. eCollection 2014.
|
| 392 |
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo.PLoS One. 2019 Oct 17;14(10):e0224015. doi: 10.1371/journal.pone.0224015. eCollection 2019.
|
| 393 |
p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China.Med Oncol. 2013 Jun;30(2):515. doi: 10.1007/s12032-013-0515-x. Epub 2013 Feb 27.
|
| 394 |
Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b.Cells. 2019 Jul 10;8(7):692. doi: 10.3390/cells8070692.
|
| 395 |
Expression of the BAD pathway is a marker of triple-negative status and poor outcome.Sci Rep. 2019 Nov 25;9(1):17496. doi: 10.1038/s41598-019-53695-0.
|
| 396 |
p63, Sharp1, and HIFs: master regulators of metastasis in triple-negative breast cancer.Cancer Res. 2013 Aug 15;73(16):4978-81. doi: 10.1158/0008-5472.CAN-13-0962. Epub 2013 Aug 2.
|
| 397 |
MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.Mol Cancer. 2018 Jan 8;17(1):4. doi: 10.1186/s12943-017-0754-0.
|
| 398 |
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
|
| 399 |
Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy.Oncol Lett. 2019 Jan;17(1):921-926. doi: 10.3892/ol.2018.9727. Epub 2018 Nov 19.
|
| 400 |
The PDGFR/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.
|
| 401 |
Identification of CHD4-1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.Life Sci. 2019 Dec 1;238:116963. doi: 10.1016/j.lfs.2019.116963. Epub 2019 Oct 19.
|
| 402 |
Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.Bioconjug Chem. 2019 Mar 20;30(3):907-919. doi: 10.1021/acs.bioconjchem.9b00028. Epub 2019 Feb 21.
|
| 403 |
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors.Nature. 2012 Jul 19;487(7407):380-4. doi: 10.1038/nature11207.
|
| 404 |
Pro-apoptotic effect of 2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.Breast Cancer Res Treat. 2017 Oct;165(3):517-527. doi: 10.1007/s10549-017-4378-2. Epub 2017 Jul 5.
|
| 405 |
Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2.Mol Cancer Res. 2019 Sep;17(9):1920-1930. doi: 10.1158/1541-7786.MCR-18-1291. Epub 2019 May 28.
|
| 406 |
DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells.Cancers (Basel). 2019 Nov 8;11(11):1762. doi: 10.3390/cancers11111762.
|
| 407 |
MicroRNA-137 Inhibits Cancer Progression by Targeting Del-1 in Triple-Negative Breast Cancer Cells.Int J Mol Sci. 2019 Dec 6;20(24):6162. doi: 10.3390/ijms20246162.
|
| 408 |
RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.Oncotarget. 2016 May 10;7(19):27567-83. doi: 10.18632/oncotarget.8375.
|
| 409 |
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11.
|
| 410 |
miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.BMC Cancer. 2017 Nov 10;17(1):745. doi: 10.1186/s12885-017-3674-x.
|
| 411 |
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.Ann Oncol. 2018 Apr 1;29(4):903-909. doi: 10.1093/annonc/mdy049.
|
| 412 |
Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.Biomed Pharmacother. 2019 Jul;115:108869. doi: 10.1016/j.biopha.2019.108869. Epub 2019 Apr 24.
|
| 413 |
I cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.BMC Cancer. 2018 May 25;18(1):595. doi: 10.1186/s12885-018-4507-2.
|
| 414 |
Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.Breast Cancer Res. 2015 Feb 22;17(1):25. doi: 10.1186/s13058-015-0527-x.
|
| 415 |
ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts.Oncogene. 2020 Jan;39(3):664-676. doi: 10.1038/s41388-019-1014-0. Epub 2019 Sep 18.
|
| 416 |
Knockdown of DNA/RNA-binding protein KIN17 promotes apoptosis of triple-negative breast cancer cells.Oncol Lett. 2019 Jan;17(1):288-293. doi: 10.3892/ol.2018.9597. Epub 2018 Oct 18.
|
| 417 |
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.Breast Cancer Res Treat. 2019 Jun;175(3):553-566. doi: 10.1007/s10549-019-05183-2. Epub 2019 Mar 9.
|
| 418 |
Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer.Histopathology. 2013 Jan;62(2):275-86. doi: 10.1111/his.12002. Epub 2012 Nov 8.
|
| 419 |
MicroRNA-589 serves as a tumor suppressor microRNA through directly targeting metastasis-associated protein 2 in breast cancer.Oncol Lett. 2019 Sep;18(3):2232-2239. doi: 10.3892/ol.2019.10548. Epub 2019 Jun 28.
|
| 420 |
MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells.Oncol Rep. 2019 Nov;42(5):1915-1923. doi: 10.3892/or.2019.7292. Epub 2019 Aug 23.
|
| 421 |
Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.ACS Appl Mater Interfaces. 2018 Nov 21;10(46):39455-39467. doi: 10.1021/acsami.8b09730. Epub 2018 Nov 9.
|
| 422 |
Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.Mol Pharm. 2018 Apr 2;15(4):1495-1504. doi: 10.1021/acs.molpharmaceut.7b01055. Epub 2018 Mar 12.
|
| 423 |
Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.Breast Cancer Res Treat. 2020 Feb;179(3):605-614. doi: 10.1007/s10549-019-05483-7. Epub 2019 Nov 25.
|
| 424 |
PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells.FEBS Lett. 2015 Apr 13;589(9):1033-9. doi: 10.1016/j.febslet.2015.03.009. Epub 2015 Mar 18.
|
| 425 |
SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.Am J Surg Pathol. 2019 Mar;43(3):293-302. doi: 10.1097/PAS.0000000000001216.
|
| 426 |
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.Clin Cancer Res. 2017 Aug 15;23(16):4780-4792. doi: 10.1158/1078-0432.CCR-16-2622. Epub 2017 May 2.
|
| 427 |
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.Nat Nanotechnol. 2019 Apr;14(4):388-397. doi: 10.1038/s41565-019-0381-6. Epub 2019 Feb 25.
|
| 428 |
CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer.Cancer Sci. 2020 Feb;111(2):383-394. doi: 10.1111/cas.14276. Epub 2020 Jan 2.
|
| 429 |
miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.Oncol Rep. 2016 Jul;36(1):65-71. doi: 10.3892/or.2016.4767. Epub 2016 Apr 25.
|
| 430 |
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.Breast Cancer Res Treat. 2018 Sep;171(2):345-357. doi: 10.1007/s10549-018-4833-8. Epub 2018 May 29.
|
| 431 |
Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo.Ann Surg Oncol. 2019 Dec;26(13):4782-4790. doi: 10.1245/s10434-019-07800-2. Epub 2019 Sep 12.
|
| 432 |
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15.
|
| 433 |
SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program.Cancer Res. 2019 Feb 15;79(4):720-734. doi: 10.1158/0008-5472.CAN-18-1791. Epub 2019 Jan 3.
|
| 434 |
SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.Oncol Rep. 2016 Apr;35(4):2405-12. doi: 10.3892/or.2016.4564. Epub 2016 Jan 15.
|
| 435 |
Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells.Tumour Biol. 2016 Oct;37(10):13101-13110. doi: 10.1007/s13277-016-5240-6. Epub 2016 Jul 23.
|
| 436 |
Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.Sci Rep. 2019 Aug 12;9(1):11632. doi: 10.1038/s41598-019-48064-w.
|
| 437 |
Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.Mol Oncol. 2019 Apr;13(4):894-908. doi: 10.1002/1878-0261.12444. Epub 2019 Mar 1.
|
| 438 |
Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo.Sci Rep. 2018 Jun 7;8(1):8701. doi: 10.1038/s41598-018-27025-9.
|
| 439 |
Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.Transl Oncol. 2019 Mar;12(3):493-501. doi: 10.1016/j.tranon.2018.11.008. Epub 2018 Dec 27.
|
| 440 |
AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.J Exp Clin Cancer Res. 2017 May 12;36(1):65. doi: 10.1186/s13046-017-0522-4.
|
| 441 |
ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086.
|
| 442 |
Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.PLoS One. 2019 Mar 15;14(3):e0209392. doi: 10.1371/journal.pone.0209392. eCollection 2019.
|
| 443 |
Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization.Biochem Biophys Res Commun. 2019 Dec 3;520(2):263-268. doi: 10.1016/j.bbrc.2019.09.133. Epub 2019 Oct 5.
|
| 444 |
ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.Mol Oncol. 2018 Jun;12(6):896-912. doi: 10.1002/1878-0261.12202. Epub 2018 Apr 18.
|
| 445 |
The expression of ANXA3 and its relationship with the occurrence and development of breast cancer.J BUON. 2018 May-Jun;23(3):713-719.
|
| 446 |
Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.J Hum Genet. 2018 Dec;63(12):1197-1210. doi: 10.1038/s10038-018-0510-3. Epub 2018 Sep 18.
|
| 447 |
ARHGAP18 Downregulation by miR-200b Suppresses Metastasis of Triple-Negative Breast Cancer by Enhancing Activation of RhoA.Cancer Res. 2017 Aug 1;77(15):4051-4064. doi: 10.1158/0008-5472.CAN-16-3141. Epub 2017 Jun 15.
|
| 448 |
Upregulated expression of AT-rich interactive domain-containing protein 1B predicts poor prognosis in patients with triple-negative breast cancer.Oncol Lett. 2019 Mar;17(3):3289-3295. doi: 10.3892/ol.2019.9961. Epub 2019 Jan 23.
|
| 449 |
Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis.Int J Oncol. 2013 Feb;42(2):478-506. doi: 10.3892/ijo.2012.1744. Epub 2012 Dec 18.
|
| 450 |
Rare ATAD5 missense variants in breast and ovarian cancer patients.Cancer Lett. 2016 Jun 28;376(1):173-7. doi: 10.1016/j.canlet.2016.03.048. Epub 2016 Apr 1.
|
| 451 |
ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes.Cells. 2018 Dec 6;7(12):248. doi: 10.3390/cells7120248.
|
| 452 |
Immunization against HIF-1 Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Clin Cancer Res. 2017 Jul 1;23(13):3396-3404. doi: 10.1158/1078-0432.CCR-16-1678. Epub 2016 Dec 30.
|
| 453 |
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.Cancer Cell. 2018 Feb 12;33(2):187-201.e10. doi: 10.1016/j.ccell.2018.01.009.
|
| 454 |
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women.Oncotarget. 2016 Mar 1;7(9):9759-72. doi: 10.18632/oncotarget.7112.
|
| 455 |
Co-chaperone BAG2 Determines the Pro-oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells.Cell Rep. 2017 Dec 5;21(10):2952-2964. doi: 10.1016/j.celrep.2017.11.026.
|
| 456 |
Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.Oncotarget. 2019 May 3;10(33):3144. doi: 10.18632/oncotarget.26920. eCollection 2019 May 3.
|
| 457 |
BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation.Theranostics. 2019 Aug 21;9(22):6468-6484. doi: 10.7150/thno.35383. eCollection 2019.
|
| 458 |
p130Cas alters the differentiation potential of mammary luminal progenitors by deregulating c-Kit activity.Stem Cells. 2013 Jul;31(7):1422-33. doi: 10.1002/stem.1403.
|
| 459 |
Roles of BCCIP deficiency in mammary tumorigenesis.Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.
|
| 460 |
Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis.Oncol Rep. 2015 Aug;34(2):961-71. doi: 10.3892/or.2015.4071. Epub 2015 Jun 16.
|
| 461 |
Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.
|
| 462 |
Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.Acta Biochim Biophys Sin (Shanghai). 2018 Nov 1;50(11):1141-1149. doi: 10.1093/abbs/gmy117.
|
| 463 |
The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria.Cell Death Differ. 2016 Oct;23(10):1702-16. doi: 10.1038/cdd.2016.61. Epub 2016 Jul 1.
|
| 464 |
Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.Oncotarget. 2017 Jan 24;8(4):6206-6215. doi: 10.18632/oncotarget.14052.
|
| 465 |
Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11076-83. eCollection 2015.
|
| 466 |
-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.Exp Mol Med. 2015 Feb 27;47(2):e143. doi: 10.1038/emm.2014.127.
|
| 467 |
A gentle approach to investigate the influence of LRP-1 silencing on the migratory behavior of breast cancer cells by atomic force microscopy and dynamic cell studies.Nanomedicine. 2019 Jun;18:359-370. doi: 10.1016/j.nano.2018.10.012. Epub 2018 Nov 10.
|
| 468 |
Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling.Chem Biol Interact. 2020 Jan 5;315:108872. doi: 10.1016/j.cbi.2019.108872. Epub 2019 Oct 24.
|
| 469 |
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.
|
| 470 |
CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation.Oncogene. 2015 Jun 11;34(24):3152-63. doi: 10.1038/onc.2014.250. Epub 2014 Aug 18.
|
| 471 |
CCN6 regulates IGF2BP2and HMGA2 signaling in metaplastic carcinomas of the breast.Breast Cancer Res Treat. 2018 Dec;172(3):577-586. doi: 10.1007/s10549-018-4960-2. Epub 2018 Sep 15.
|
| 472 |
CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.Cell Physiol Biochem. 2017;43(1):94-107. doi: 10.1159/000480322. Epub 2017 Aug 25.
|
| 473 |
Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.Mol Cancer. 2015 Feb 10;14:36. doi: 10.1186/s12943-015-0301-9.
|
| 474 |
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 May;18(5):873-885.
|
| 475 |
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26.
|
| 476 |
New halogenated constituents from Mangifera zeylanica Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells.J Ethnopharmacol. 2016 Aug 2;189:165-74. doi: 10.1016/j.jep.2016.05.047. Epub 2016 May 17.
|
| 477 |
MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.Med Sci Monit. 2015 May 6;21:1297-303. doi: 10.12659/MSM.893974.
|
| 478 |
Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells in vitro and in vivo.Oncol Lett. 2019 May;17(5):4393-4400. doi: 10.3892/ol.2019.10077. Epub 2019 Feb 26.
|
| 479 |
Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.Int J Cancer. 2018 Nov 15;143(10):2602-2613. doi: 10.1002/ijc.31766. Epub 2018 Sep 19.
|
| 480 |
Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.Int J Oncol. 2014 Jun;44(6):2025-33. doi: 10.3892/ijo.2014.2352. Epub 2014 Mar 20.
|
| 481 |
Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.Cancer Lett. 2020 Jul 10;482:102-111. doi: 10.1016/j.canlet.2019.11.003. Epub 2019 Nov 6.
|
| 482 |
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.J Exp Clin Cancer Res. 2018 Dec 14;37(1):314. doi: 10.1186/s13046-018-0988-8.
|
| 483 |
miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.J Cell Physiol. 2020 Mar;235(3):2825-2835. doi: 10.1002/jcp.29188. Epub 2019 Sep 20.
|
| 484 |
CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer.Sci Rep. 2017 Sep 18;7(1):11802. doi: 10.1038/s41598-017-12306-6.
|
| 485 |
Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.J Cancer. 2019 Oct 15;10(24):5964-5974. doi: 10.7150/jca.35704. eCollection 2019.
|
| 486 |
Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.Am J Cancer Res. 2018 Jun 1;8(6):1050-1063. eCollection 2018.
|
| 487 |
siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.Oncotarget. 2017 Jan 10;8(2):2585-2593. doi: 10.18632/oncotarget.13716.
|
| 488 |
miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer.Mol Oncol. 2014 Dec;8(8):1690-702. doi: 10.1016/j.molonc.2014.07.006. Epub 2014 Jul 12.
|
| 489 |
Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer.Clin Exp Pharmacol Physiol. 2019 Sep;46(9):837-844. doi: 10.1111/1440-1681.13104. Epub 2019 Jun 10.
|
| 490 |
CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.BMC Cancer. 2018 Aug 13;18(1):813. doi: 10.1186/s12885-018-4724-8.
|
| 491 |
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.Oncotarget. 2015 Sep 22;6(28):25356-67. doi: 10.18632/oncotarget.4516.
|
| 492 |
CUL1 Knockdown Attenuates the Adhesion, Invasion, and Migration of Triple-Negative Breast Cancer Cells via Inhibition of Epithelial-Mesenchymal Transition.Pathol Oncol Res. 2020 Apr;26(2):1153-1163. doi: 10.1007/s12253-019-00681-6. Epub 2019 Jun 7.
|
| 493 |
Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.J Cell Biochem. 2019 Apr;120(4):6004-6014. doi: 10.1002/jcb.27887. Epub 2018 Nov 18.
|
| 494 |
Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells.Eur J Pharmacol. 2017 May 15;803:130-137. doi: 10.1016/j.ejphar.2017.03.049. Epub 2017 Mar 23.
|
| 495 |
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.Cell Signal. 2018 Apr;44:33-42. doi: 10.1016/j.cellsig.2018.01.013. Epub 2018 Jan 12.
|
| 496 |
Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5... Asian Pac J Cancer Prev. 2015;16(2):541-9.
|
| 497 |
DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.Neoplasia. 2019 Jun;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. Epub 2019 Apr 24.
|
| 498 |
Blood pressure and risk of breast cancer, overall and by subtypes: a prospective cohort study.J Hypertens. 2017 Jul;35(7):1371-1380. doi: 10.1097/HJH.0000000000001372.
|
| 499 |
Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells.Sci Rep. 2019 Sep 24;9(1):13748. doi: 10.1038/s41598-019-50141-z.
|
| 500 |
Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.Cancer Sci. 2019 Nov;110(11):3543-3552. doi: 10.1111/cas.14201. Epub 2019 Oct 6.
|
| 501 |
Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer.Nat Commun. 2019 Jun 28;10(1):2860. doi: 10.1038/s41467-019-10743-7.
|
| 502 |
Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells.Cell. 2019 Aug 22;178(5):1189-1204.e23. doi: 10.1016/j.cell.2019.07.044.
|
| 503 |
ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.Mol Cancer Ther. 2015 Apr;14(4):877-88. doi: 10.1158/1535-7163.MCT-14-1093-T. Epub 2015 Jan 22.
|
| 504 |
Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression.Biomed Pharmacother. 2017 Oct;94:439-445. doi: 10.1016/j.biopha.2017.07.119. Epub 2017 Aug 2.
|
| 505 |
EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming.Nat Commun. 2019 Nov 6;10(1):5033. doi: 10.1038/s41467-019-13034-3.
|
| 506 |
EgoNet: identification of human disease ego-network modules.BMC Genomics. 2014 Apr 28;15:314. doi: 10.1186/1471-2164-15-314.
|
| 507 |
Proteomics Identification and Validation of Desmocollin-1 and Catechol-O-Methyltransferase as Proteins Associated with Breast Cancer Cell Migration and Metastasis.Proteomics. 2019 Nov;19(21-22):e1900073. doi: 10.1002/pmic.201900073. Epub 2019 Oct 28.
|
| 508 |
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.Int J Mol Sci. 2019 Jun 24;20(12):3080. doi: 10.3390/ijms20123080.
|
| 509 |
Acetylation of conserved DVL-1 lysines regulates its nuclear translocation and binding to gene promoters in triple-negative breast cancer.Sci Rep. 2019 Nov 7;9(1):16257. doi: 10.1038/s41598-019-52723-3.
|
| 510 |
miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.Mol Cancer Ther. 2014 Dec;13(12):3185-97. doi: 10.1158/1535-7163.MCT-14-0243. Epub 2014 Oct 15.
|
| 511 |
ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.Br J Cancer. 2019 Apr;120(9):931-940. doi: 10.1038/s41416-019-0448-z. Epub 2019 Apr 11.
|
| 512 |
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis.PLoS One. 2019 Jun 20;14(6):e0218030. doi: 10.1371/journal.pone.0218030. eCollection 2019.
|
| 513 |
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23.
|
| 514 |
MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.Oncotarget. 2017 Mar 21;8(12):19455-19466. doi: 10.18632/oncotarget.14307.
|
| 515 |
The CXCR4-LASP1-eIF4F Axis Promotes Translation of Oncogenic Proteins in Triple-Negative Breast Cancer Cells.Front Oncol. 2019 Apr 24;9:284. doi: 10.3389/fonc.2019.00284. eCollection 2019.
|
| 516 |
Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway.Oncol Lett. 2018 Sep;16(3):3481-3488. doi: 10.3892/ol.2018.9077. Epub 2018 Jul 4.
|
| 517 |
Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.BMC Cancer. 2017 Aug 29;17(1):589. doi: 10.1186/s12885-017-3554-4.
|
| 518 |
Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.Int J Cancer. 2019 Nov 15;145(10):2850-2860. doi: 10.1002/ijc.32329. Epub 2019 Apr 29.
|
| 519 |
Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation.PLoS One. 2015 Jan 15;10(1):e0115352. doi: 10.1371/journal.pone.0115352. eCollection 2015.
|
| 520 |
Combined genetic and nutritional risk models of triple negative breast cancer.Nutr Cancer. 2014;66(6):955-63. doi: 10.1080/01635581.2014.932397. Epub 2014 Jul 14.
|
| 521 |
Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer.Cell Death Dis. 2019 Jun 3;10(6):428. doi: 10.1038/s41419-019-1662-6.
|
| 522 |
Endocan as a prognostic biomarker of triple-negative breast cancer.Breast Cancer Res Treat. 2017 Jan;161(2):269-278. doi: 10.1007/s10549-016-4057-8. Epub 2016 Nov 25.
|
| 523 |
The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.J Cell Biochem. 2017 Sep;118(9):2559-2570. doi: 10.1002/jcb.25974. Epub 2017 May 3.
|
| 524 |
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.
|
| 525 |
FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control.Front Oncol. 2019 Oct 24;9:1089. doi: 10.3389/fonc.2019.01089. eCollection 2019.
|
| 526 |
Metabolic role of fatty acid binding protein 7 in mediating triple-negative breast cancer cell death via PPAR- signaling.J Lipid Res. 2019 Nov;60(11):1807-1817. doi: 10.1194/jlr.M092379. Epub 2019 Sep 4.
|
| 527 |
Estrogen receptor- regulation of microRNA-590 targets FAM171A1-a modifier of breast cancer invasiveness.Oncogenesis. 2019 Jan 9;8(1):5. doi: 10.1038/s41389-018-0113-z.
|
| 528 |
Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer.Mol Biosyst. 2016 Jun 21;12(7):2108-18. doi: 10.1039/c6mb00111d.
|
| 529 |
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
|
| 530 |
FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.Breast Cancer Res Treat. 2017 Nov;166(1):217-226. doi: 10.1007/s10549-017-4388-0. Epub 2017 Jul 12.
|
| 531 |
The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.Acta Pharmacol Sin. 2017 Apr;38(4):513-523. doi: 10.1038/aps.2016.136. Epub 2017 Jan 2.
|
| 532 |
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
|
| 533 |
Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities.Breast Cancer (Auckl). 2018 Aug 24;12:1178223418792247. doi: 10.1177/1178223418792247. eCollection 2018.
|
| 534 |
Identification of FOXE3 transcription factor as a potent oncogenic factor in triple-negative breast cancer.Biochem Biophys Res Commun. 2020 Feb 26;523(1):78-85. doi: 10.1016/j.bbrc.2019.12.034. Epub 2019 Dec 9.
|
| 535 |
microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer.Oncogene. 2018 May;37(22):2982-2991. doi: 10.1038/s41388-018-0124-4. Epub 2018 Mar 12.
|
| 536 |
FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.J Clin Pathol. 2018 Sep;71(9):806-813. doi: 10.1136/jclinpath-2018-205052. Epub 2018 Mar 27.
|
| 537 |
FSIP1 regulates autophagy in breast cancer.Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13075-13080. doi: 10.1073/pnas.1809681115. Epub 2018 Dec 3.
|
| 538 |
Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.Mol Cancer Ther. 2013 Apr;12(4):491-8. doi: 10.1158/1535-7163.MCT-12-1090. Epub 2013 Feb 27.
|
| 539 |
GABARAPL1 acts as a potential marker and promotes tumor proliferation and metastasis in triple negative breast cancer.Oncotarget. 2017 Aug 10;8(43):74519-74526. doi: 10.18632/oncotarget.20159. eCollection 2017 Sep 26.
|
| 540 |
A soluble form of GAS1 inhibits tumor growth and angiogenesis in a triple negative breast cancer model.Exp Cell Res. 2014 Oct 1;327(2):307-17. doi: 10.1016/j.yexcr.2014.06.016. Epub 2014 Jun 30.
|
| 541 |
Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.BMC Cancer. 2017 Nov 7;17(1):727. doi: 10.1186/s12885-017-3726-2.
|
| 542 |
GDF10 inhibits proliferation and epithelial-mesenchymal transition in triple-negative breast cancer via upregulation of Smad7.Aging (Albany NY). 2019 May 31;11(10):3298-3314. doi: 10.18632/aging.101983.
|
| 543 |
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.Tumour Biol. 2016 Jun;37(6):8159-68. doi: 10.1007/s13277-015-4729-8. Epub 2015 Dec 29.
|
| 544 |
circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.J Exp Clin Cancer Res. 2017 Oct 16;36(1):145. doi: 10.1186/s13046-017-0614-1.
|
| 545 |
GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.Breast Cancer Res Treat. 2019 Feb;174(1):65-78. doi: 10.1007/s10549-018-5052-z. Epub 2018 Nov 19.
|
| 546 |
GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.Gene. 2017 Sep 10;628:224-229. doi: 10.1016/j.gene.2017.07.054. Epub 2017 Jul 20.
|
| 547 |
Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer.J Breast Cancer. 2018 Mar;21(1):87-90. doi: 10.4048/jbc.2018.21.1.87. Epub 2018 Mar 23.
|
| 548 |
GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.J Exp Clin Cancer Res. 2019 Apr 8;38(1):152. doi: 10.1186/s13046-019-1157-4.
|
| 549 |
Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase.J Oncol. 2019 Jun 2;2019:1345026. doi: 10.1155/2019/1345026. eCollection 2019.
|
| 550 |
Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer.Oncol Lett. 2019 Dec;18(6):6775-6780. doi: 10.3892/ol.2019.11001. Epub 2019 Oct 18.
|
| 551 |
Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.Neoplasia. 2019 Oct;21(10):963-973. doi: 10.1016/j.neo.2019.07.001. Epub 2019 Aug 19.
|
| 552 |
Identification of sample-specific regulations using integrative network level analysis.BMC Cancer. 2015 Apr 28;15:319. doi: 10.1186/s12885-015-1265-2.
|
| 553 |
hnRNPK S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells.Sci Rep. 2019 May 20;9(1):7611. doi: 10.1038/s41598-019-44063-z.
|
| 554 |
Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.Cancer Res. 2018 Oct 15;78(20):5780-5792. doi: 10.1158/0008-5472.CAN-17-1394. Epub 2018 Aug 9.
|
| 555 |
Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.J Cell Physiol. 2019 Aug;234(8):13303-13317. doi: 10.1002/jcp.28007. Epub 2019 Jan 7.
|
| 556 |
Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.Mol Carcinog. 2019 Oct;58(10):1863-1875. doi: 10.1002/mc.23079. Epub 2019 Jul 1.
|
| 557 |
Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.Clin Breast Cancer. 2019 Oct;19(5):326-332.e1. doi: 10.1016/j.clbc.2019.03.008. Epub 2019 Apr 11.
|
| 558 |
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.Exp Mol Pathol. 2015 Aug;99(1):180-7. doi: 10.1016/j.yexmp.2015.06.010. Epub 2015 Jun 22.
|
| 559 |
Baicalein Suppresses Stem Cell-Like Characteristics in Radio- and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2.Nutrients. 2019 Mar 14;11(3):624. doi: 10.3390/nu11030624.
|
| 560 |
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.Mol Cancer Ther. 2016 Jul;15(7):1545-56. doi: 10.1158/1535-7163.MCT-15-0865. Epub 2016 May 11.
|
| 561 |
IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.Cancer Res. 2014 Sep 1;74(17):4908-21. doi: 10.1158/0008-5472.CAN-14-0637. Epub 2014 Jun 30.
|
| 562 |
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.Tumour Biol. 2014 May;35(5):4469-77. doi: 10.1007/s13277-013-1589-y. Epub 2014 Jan 14.
|
| 563 |
Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13792-13797. doi: 10.1073/pnas.1713728114. Epub 2017 Dec 11.
|
| 564 |
Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclicoctapeptide modified liposomes for targeting integrin 3 in triple-negative breast cancer.Biomaterials. 2014 Jul;35(20):5347-5358. doi: 10.1016/j.biomaterials.2014.03.036. Epub 2014 Apr 13.
|
| 565 |
Integrin 9 depletion promotes -catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.Int J Cancer. 2019 Nov 15;145(10):2767-2780. doi: 10.1002/ijc.32359. Epub 2019 May 3.
|
| 566 |
Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells.BMC Cancer. 2016 Aug 31;16(1):700. doi: 10.1186/s12885-016-2683-5.
|
| 567 |
MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase C-based triple-negative breast cancer cells.Oncotarget. 2016 Sep 13;7(37):59845-59859. doi: 10.18632/oncotarget.11337.
|
| 568 |
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.Acta Biochim Biophys Sin (Shanghai). 2018 Sep 1;50(9):897-904. doi: 10.1093/abbs/gmy084.
|
| 569 |
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10325-34. eCollection 2015.
|
| 570 |
KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
|
| 571 |
Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.Curr Mol Med. 2019;19(2):147-155. doi: 10.2174/1566524019666190308122108.
|
| 572 |
circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.Mol Cancer. 2019 Feb 11;18(1):23. doi: 10.1186/s12943-019-0946-x.
|
| 573 |
Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer.Sci Rep. 2017 Feb 20;7:42289. doi: 10.1038/srep42289.
|
| 574 |
MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.Cancer Cell Int. 2018 Jan 30;18:16. doi: 10.1186/s12935-018-0512-4. eCollection 2018.
|
| 575 |
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.Cancer Biol Ther. 2017 May 4;18(5):339-346. doi: 10.1080/15384047.2017.1312230. Epub 2017 Apr 7.
|
| 576 |
Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.Pathol Res Pract. 2018 Oct;214(10):1626-1631. doi: 10.1016/j.prp.2018.08.009. Epub 2018 Aug 17.
|
| 577 |
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.
|
| 578 |
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.Oncotarget. 2017 Feb 14;8(7):11977-11989. doi: 10.18632/oncotarget.14450.
|
| 579 |
Lipin-1 regulation of phospholipid synthesis maintains endoplasmic reticulum homeostasis and is critical for triple-negative breast cancer cell survival.FASEB J. 2017 Jul;31(7):2893-2904. doi: 10.1096/fj.201601353R. Epub 2017 Mar 27.
|
| 580 |
Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.Mol Biol Rep. 2019 Dec;46(6):6617-6624. doi: 10.1007/s11033-019-05079-w. Epub 2019 Sep 24.
|
| 581 |
Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.Cancer Lett. 2018 Dec 1;438:165-173. doi: 10.1016/j.canlet.2018.09.022. Epub 2018 Sep 15.
|
| 582 |
Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.Int J Oncol. 2018 May;52(5):1539-1558. doi: 10.3892/ijo.2018.4301. Epub 2018 Mar 5.
|
| 583 |
miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.Oncol Lett. 2019 Jan;17(1):990-998. doi: 10.3892/ol.2018.9687. Epub 2018 Nov 12.
|
| 584 |
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR(+) Metastatic Triple-Negative Breast Cancer.Clin Cancer Res. 2020 May 1;26(9):2111-2123. doi: 10.1158/1078-0432.CCR-19-2170. Epub 2019 Dec 10.
|
| 585 |
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.
|
| 586 |
Role of Wnt Co-Receptor LRP6 in Triple Negative Breast Cancer Cell Migration and Invasion.J Cell Biochem. 2017 Sep;118(9):2968-2976. doi: 10.1002/jcb.25956. Epub 2017 May 30.
|
| 587 |
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.Cancer Biomark. 2016;16(1):145-52. doi: 10.3233/CBM-150550.
|
| 588 |
Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase.Nat Commun. 2018 Feb 8;9(1):578. doi: 10.1038/s41467-018-02938-1.
|
| 589 |
Non-SMC Condensin I Complex Subunit D2 Is a Prognostic Factor in Triple-Negative Breast Cancer for the Ability to Promote Cell Cycle and Enhance Invasion.Am J Pathol. 2020 Jan;190(1):37-47. doi: 10.1016/j.ajpath.2019.09.014. Epub 2019 Oct 12.
|
| 590 |
Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer.Oncol Lett. 2018 Jul;16(1):91-96. doi: 10.3892/ol.2018.8689. Epub 2018 May 10.
|
| 591 |
The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.Oncogene. 2018 Jul;37(28):3879-3893. doi: 10.1038/s41388-018-0239-7. Epub 2018 Apr 17.
|
| 592 |
Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research.J Cell Physiol. 2018 Oct;233(10):6603-6612. doi: 10.1002/jcp.26311. Epub 2018 Apr 17.
|
| 593 |
Inhibition of the Proteasome 2 Site Sensitizes Triple-Negative Breast Cancer Cells to 5 Inhibitors and Suppresses Nrf1 Activation.Cell Chem Biol. 2017 Feb 16;24(2):218-230. doi: 10.1016/j.chembiol.2016.12.016. Epub 2017 Jan 26.
|
| 594 |
Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells.Oncol Lett. 2018 Jun;15(6):8784-8788. doi: 10.3892/ol.2018.8434. Epub 2018 Apr 5.
|
| 595 |
Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.Acta Pharmacol Sin. 2019 Aug;40(8):1067-1075. doi: 10.1038/s41401-018-0199-z. Epub 2019 Jan 22.
|
| 596 |
Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.Int J Oncol. 2018 Jan;52(1):67-76. doi: 10.3892/ijo.2017.4204. Epub 2017 Nov 14.
|
| 597 |
PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.Cancer Lett. 2017 Nov 28;409:30-41. doi: 10.1016/j.canlet.2017.08.019. Epub 2017 Aug 24.
|
| 598 |
Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.ACS Med Chem Lett. 2019 Jul 25;10(9):1328-1335. doi: 10.1021/acsmedchemlett.9b00284. eCollection 2019 Sep 12.
|
| 599 |
PCDHGB7 Increases Chemosensitivity to Carboplatin by Inhibiting HSPA9 via Inducing Apoptosis in Breast Cancer.Dis Markers. 2019 Jul 8;2019:6131548. doi: 10.1155/2019/6131548. eCollection 2019.
|
| 600 |
MEL-18 loss mediates estrogen receptor- downregulation and hormone independence.J Clin Invest. 2015 May;125(5):1801-14. doi: 10.1172/JCI73743. Epub 2015 Mar 30.
|
| 601 |
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.Cancer Immunol Immunother. 2017 Dec;66(12):1529-1544. doi: 10.1007/s00262-017-2047-2. Epub 2017 Aug 2.
|
| 602 |
Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.Tumour Biol. 2013 Jun;34(3):1713-22. doi: 10.1007/s13277-013-0708-0. Epub 2013 Feb 22.
|
| 603 |
Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migration.Biomed Res Int. 2014;2014:536591. doi: 10.1155/2014/536591. Epub 2014 May 6.
|
| 604 |
PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.
|
| 605 |
Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells.Anticancer Res. 2013 Feb;33(2):393-9.
|
| 606 |
The Gh-PLC1 signaling axis drives metastatic progression in triple-negative breast cancer.J Hematol Oncol. 2017 Jun 2;10(1):114. doi: 10.1186/s13045-017-0481-4.
|
| 607 |
Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.Sci Rep. 2017 Jun 12;7(1):3301. doi: 10.1038/s41598-017-03280-0.
|
| 608 |
LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9.Biosci Biotechnol Biochem. 2019 Jun;83(6):1117-1123. doi: 10.1080/09168451.2019.1588097. Epub 2019 Mar 7.
|
| 609 |
Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer.Oncotarget. 2019 Apr 2;10(26):2515-2529. doi: 10.18632/oncotarget.26808. eCollection 2019 Apr 2.
|
| 610 |
PRDM14 directly interacts with heat shock proteins HSP90 and glucose-regulated protein 78.Cancer Sci. 2018 Feb;109(2):373-383. doi: 10.1111/cas.13458. Epub 2017 Dec 28.
|
| 611 |
Inhibition on the growth of human MDA-MB-231 breast cancer cells in vitro and tumor growth in a mouse xenograft model by Se-containing polysaccharides from Pyracantha fortuneana.Nutr Res. 2016 Nov;36(11):1243-1254. doi: 10.1016/j.nutres.2016.09.012. Epub 2016 Oct 2.
|
| 612 |
Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.Cell Res. 2019 Oct;29(10):832-845. doi: 10.1038/s41422-019-0225-9. Epub 2019 Sep 3.
|
| 613 |
miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.J Cell Mol Med. 2016 May;20(5):864-73. doi: 10.1111/jcmm.12770. Epub 2016 Jan 28.
|
| 614 |
MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.Cell Physiol Biochem. 2017;44(5):1785-1795. doi: 10.1159/000485785. Epub 2017 Dec 6.
|
| 615 |
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.
|
| 616 |
NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.Oncogenesis. 2018 May 25;7(5):42. doi: 10.1038/s41389-018-0051-9.
|
| 617 |
LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer.J Cancer. 2019 May 12;10(9):2018-2024. doi: 10.7150/jca.29670. eCollection 2019.
|
| 618 |
Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells.Oncol Rep. 2017 Mar;37(3):1619-1626. doi: 10.3892/or.2017.5404. Epub 2017 Jan 25.
|
| 619 |
IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.Breast Cancer Res Treat. 2018 Dec;172(3):551-560. doi: 10.1007/s10549-018-4941-5. Epub 2018 Aug 28.
|
| 620 |
Gene and lncRNA co-expression network analysis reveals novel ceRNA network for triple-negative breast cancer.Sci Rep. 2019 Oct 22;9(1):15122. doi: 10.1038/s41598-019-51626-7.
|
| 621 |
Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.Ann Oncol. 2018 Oct 1;29(10):2046-2051. doi: 10.1093/annonc/mdy338.
|
| 622 |
Gene expression in triple-negative breast cancer in relation to survival.Breast Cancer Res Treat. 2018 Aug;171(1):199-207. doi: 10.1007/s10549-018-4816-9. Epub 2018 May 10.
|
| 623 |
Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2340-2347. doi: 10.1016/j.bbrc.2018.06.159. Epub 2018 Jul 2.
|
| 624 |
LINC00096 Promotes the Proliferation and Invasion by Sponging miR-383-5p and Regulating RBM3 Expression in Triple-Negative Breast Cancer.Onco Targets Ther. 2019 Dec 2;12:10569-10578. doi: 10.2147/OTT.S229659. eCollection 2019.
|
| 625 |
The DNA repair helicase RECQ1 has a checkpoint-dependent role in mediating DNA damage responses induced by gemcitabine.J Biol Chem. 2019 Oct 18;294(42):15330-15345. doi: 10.1074/jbc.RA119.008420. Epub 2019 Aug 23.
|
| 626 |
RECQL5 plays an essential role in maintaining genome stability and viability of triple-negative breast cancer cells.Cancer Med. 2019 Aug;8(10):4743-4752. doi: 10.1002/cam4.2349. Epub 2019 Jun 23.
|
| 627 |
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT.Transl Oncol. 2017 Feb;10(1):1-9. doi: 10.1016/j.tranon.2016.10.004. Epub 2016 Nov 23.
|
| 628 |
Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.Biochem Biophys Res Commun. 2017 Apr 8;485(3):693-697. doi: 10.1016/j.bbrc.2017.02.106. Epub 2017 Feb 22.
|
| 629 |
MicroRNA?26?p inhibits the proliferation, migration, invasion, and angiogenesis of triplenegative breast cancer cells by targeting RGS3.Oncol Rep. 2019 Oct;42(4):1569-1579. doi: 10.3892/or.2019.7251. Epub 2019 Jul 26.
|
| 630 |
(212)Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.Int J Mol Sci. 2018 Mar 21;19(4):925. doi: 10.3390/ijms19040925.
|
| 631 |
Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer.Genet Mol Biol. 2020 Mar 2;43(1):e20180269. doi: 10.1590/1678-4685-GMB-2018-0269. eCollection 2020.
|
| 632 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.Genes Cells. 2013 Dec;18(12):1120-30. doi: 10.1111/gtc.12100. Epub 2013 Oct 28.
|
| 633 |
The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers.Oncogene. 2019 Mar;38(12):2020-2041. doi: 10.1038/s41388-018-0586-4. Epub 2018 Nov 22.
|
| 634 |
Role of RPL39 in Metaplastic Breast Cancer.J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun.
|
| 635 |
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.Int J Oncol. 2018 Mar;52(3):828-840. doi: 10.3892/ijo.2018.4244. Epub 2018 Jan 15.
|
| 636 |
TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.Mol Cancer Ther. 2017 Jul;16(7):1377-1388. doi: 10.1158/1535-7163.MCT-17-0026. Epub 2017 Apr 17.
|
| 637 |
CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data.BMC Med Genomics. 2017 Mar 15;10(1):15. doi: 10.1186/s12920-017-0255-4.
|
| 638 |
Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population.Mol Cell Biochem. 2018 May;442(1-2):1-10. doi: 10.1007/s11010-017-3187-6. Epub 2017 Sep 16.
|
| 639 |
MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer.Gene. 2016 Dec 5;594(1):47-58. doi: 10.1016/j.gene.2016.08.057. Epub 2016 Sep 1.
|
| 640 |
SCYL1 does not regulate REST expression and turnover.PLoS One. 2017 Jun 1;12(6):e0178680. doi: 10.1371/journal.pone.0178680. eCollection 2017.
|
| 641 |
Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.J Proteomics. 2020 Feb 10;212:103581. doi: 10.1016/j.jprot.2019.103581. Epub 2019 Nov 12.
|
| 642 |
The role of sentrin-specific protease 2 substrate recognition in TGF--induced tumorigenesis.Sci Rep. 2018 Jun 28;8(1):9786. doi: 10.1038/s41598-018-28103-8.
|
| 643 |
Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer.Sci Rep. 2019 Nov 6;9(1):16131. doi: 10.1038/s41598-019-52718-0.
|
| 644 |
The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential.Int J Mol Sci. 2016 Apr 21;17(4):606. doi: 10.3390/ijms17040606.
|
| 645 |
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.EBioMedicine. 2019 Feb;40:263-275. doi: 10.1016/j.ebiom.2018.12.032. Epub 2019 Jan 14.
|
| 646 |
MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.Br J Cancer. 2017 Jun 27;117(1):78-88. doi: 10.1038/bjc.2017.150. Epub 2017 Jun 1.
|
| 647 |
MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer.Mol Carcinog. 2016 May;55(5):768-77. doi: 10.1002/mc.22320. Epub 2015 Apr 7.
|
| 648 |
Integrated Bioinformatics Data Analysis Reveals Prognostic Significance Of SIDT1 In Triple-Negative Breast Cancer.Onco Targets Ther. 2019 Oct 11;12:8401-8410. doi: 10.2147/OTT.S215898. eCollection 2019.
|
| 649 |
SIN3A and SIN3B differentially regulate breast cancer metastasis.Oncotarget. 2016 Nov 29;7(48):78713-78725. doi: 10.18632/oncotarget.12805.
|
| 650 |
Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.Breast Cancer Res Treat. 2019 Nov;178(1):185-197. doi: 10.1007/s10549-019-05366-x. Epub 2019 Jul 24.
|
| 651 |
SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.Oncotarget. 2014 Aug 15;5(15):5920-33. doi: 10.18632/oncotarget.1874.
|
| 652 |
Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.Cell Physiol Biochem. 2019;53(6):999-1014. doi: 10.33594/000000191.
|
| 653 |
Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.Ann Surg Oncol. 2018 Oct;25(10):2867-2874. doi: 10.1245/s10434-018-6578-3. Epub 2018 Jun 28.
|
| 654 |
SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.Mol Cell Biol. 2013 Aug;33(15):3011-25. doi: 10.1128/MCB.01443-12. Epub 2013 May 28.
|
| 655 |
PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.Cancer Lett. 2016 Oct 1;380(2):505-512. doi: 10.1016/j.canlet.2016.07.017. Epub 2016 Jul 21.
|
| 656 |
Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.BMC Cancer. 2014 Feb 3;14:57. doi: 10.1186/1471-2407-14-57.
|
| 657 |
Use of Antimetastatic SOD3-Mimetic Albumin as a Primer in Triple Negative Breast Cancer.J Oncol. 2019 Feb 28;2019:3253696. doi: 10.1155/2019/3253696. eCollection 2019.
|
| 658 |
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.Cancer Biol Ther. 2018 May 4;19(5):373-380. doi: 10.1080/15384047.2018.1423919. Epub 2018 Feb 16.
|
| 659 |
Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.Breast Cancer Res. 2018 Sep 3;20(1):101. doi: 10.1186/s13058-018-1039-2.
|
| 660 |
Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.Oncotarget. 2017 Apr 25;8(17):28939-28958. doi: 10.18632/oncotarget.15960.
|
| 661 |
LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer.Oncogene. 2018 Nov;37(47):6166-6179. doi: 10.1038/s41388-018-0396-8. Epub 2018 Jul 12.
|
| 662 |
SAR optimization studies on a novel series of 2-anilinopyrimidines as selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.Bioorg Med Chem Lett. 2019 Dec 15;29(24):126752. doi: 10.1016/j.bmcl.2019.126752. Epub 2019 Oct 24.
|
| 663 |
SSBP1 Suppresses TGF-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling.Cancer Res. 2016 Feb 15;76(4):952-64. doi: 10.1158/0008-5472.CAN-15-1630. Epub 2015 Dec 16.
|
| 664 |
Hypoxia and serum deprivation induces glycan alterations in triple negative breast cancer cells.Biol Chem. 2018 Jun 27;399(7):661-672. doi: 10.1515/hsz-2018-0121.
|
| 665 |
MiR-214-3p regulates the viability, invasion, migration and EMT of TNBC cells by targeting ST6GAL1.Cytotechnology. 2019 Dec;71(6):1155-1165. doi: 10.1007/s10616-019-00352-z. Epub 2019 Nov 8.
|
| 666 |
ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.Mol Cancer Ther. 2018 Dec;17(12):2689-2701. doi: 10.1158/1535-7163.MCT-18-0399. Epub 2018 Sep 20.
|
| 667 |
PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.Cancer Discov. 2019 Jun;9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. Epub 2019 Apr 23.
|
| 668 |
Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.J Pathol. 2018 Jan;244(1):71-83. doi: 10.1002/path.4995.
|
| 669 |
Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.Cancer Biol Ther. 2019;20(5):617-632. doi: 10.1080/15384047.2018.1539290. Epub 2018 Nov 21.
|
| 670 |
Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer.Med Oncol. 2014 Apr;31(4):868. doi: 10.1007/s12032-014-0868-9. Epub 2014 Feb 22.
|
| 671 |
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.
|
| 672 |
Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics.Oncol Lett. 2018 Jan;15(1):1037-1045. doi: 10.3892/ol.2017.7402. Epub 2017 Nov 14.
|
| 673 |
Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.Theranostics. 2019 Jan 24;9(3):761-777. doi: 10.7150/thno.29520. eCollection 2019.
|
| 674 |
Circ-TFCP2L1 Promotes the Proliferation and Migration of Triple Negative Breast Cancer through Sponging miR-7 by Inhibiting PAK1.J Mammary Gland Biol Neoplasia. 2019 Dec;24(4):323-331. doi: 10.1007/s10911-019-09440-4. Epub 2019 Nov 27.
|
| 675 |
Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.
|
| 676 |
Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.Int J Oncol. 2019 Jul;55(1):116-130. doi: 10.3892/ijo.2019.4796. Epub 2019 May 6.
|
| 677 |
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.PLoS One. 2017 Feb 24;12(2):e0172832. doi: 10.1371/journal.pone.0172832. eCollection 2017.
|
| 678 |
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.Cancer Cell. 2019 Jan 14;35(1):64-80.e7. doi: 10.1016/j.ccell.2018.11.016. Epub 2019 Jan 3.
|
| 679 |
MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1.Cancer Manag Res. 2019 Jul 22;11:6755-6764. doi: 10.2147/CMAR.S199027. eCollection 2019.
|
| 680 |
TMEM17 promotes malignant progression of breast cancer via AKT/GSK3 signaling.Cancer Manag Res. 2018 Aug 2;10:2419-2428. doi: 10.2147/CMAR.S168723. eCollection 2018.
|
| 681 |
Cytosolic TMEM88 promotes triple-negative breast cancer by interacting with Dvl.Oncotarget. 2015 Sep 22;6(28):25034-45. doi: 10.18632/oncotarget.4379.
|
| 682 |
Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.Biomacromolecules. 2019 Feb 11;20(2):835-845. doi: 10.1021/acs.biomac.8b01449. Epub 2018 Dec 28.
|
| 683 |
Tribbles Homolog 3 Involved in Radiation Response of Triple Negative Breast Cancer Cells by Regulating Notch1 Activation.Cancers (Basel). 2019 Jan 22;11(2):127. doi: 10.3390/cancers11020127.
|
| 684 |
Characterization of ceRNA network to reveal potential prognostic biomarkers in triple-negative breast cancer.PeerJ. 2019 Sep 9;7:e7522. doi: 10.7717/peerj.7522. eCollection 2019.
|
| 685 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.Medicine (Baltimore). 2018 Apr;97(15):e0349. doi: 10.1097/MD.0000000000010349.
|
| 686 |
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.Cancer Res. 2012 Nov 15;72(22):5812-23. doi: 10.1158/0008-5472.CAN-12-1098. Epub 2012 Nov 8.
|
| 687 |
Tumor suppressor function of Rab25 in triple-negative breast cancer.Int J Cancer. 2010 Jun 15;126(12):2799-812. doi: 10.1002/ijc.24900.
|
| 688 |
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22.
|
| 689 |
TIPIN depletion leads to apoptosis in breast cancer cells.Mol Oncol. 2015 Oct;9(8):1580-98. doi: 10.1016/j.molonc.2015.04.010. Epub 2015 May 9.
|
| 690 |
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.
|
| 691 |
Common breast cancer susceptibility loci are associated with triple-negative breast cancer.Cancer Res. 2011 Oct 1;71(19):6240-9. doi: 10.1158/0008-5472.CAN-11-1266. Epub 2011 Aug 15.
|
|
|
|
|
|
|
